Insulin-like growth factor (IGF-1) mutant and fatty acid-modified derivative thereof

By designing IGF-1 mutants conjugated with fatty acid carriers, the half-life of IGF-1 was prolonged, solving the problem of short half-life of IGF-1 drugs, reducing the risk of hypoglycemia, and improving treatment efficacy.

WO2026237991A1PCT designated stage Publication Date: 2026-11-19CHANGCHUN GENESCIENCE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096656
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-05-11
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing IGF-1 drugs have short half-lives, require frequent administration, leading to a high risk of hypoglycemia, and lack effective drugs for treating bronchopulmonary dysplasia and acute ischemic injury, resulting in insufficient efficacy.

Method used

By conjugating IGF-1 with a fatty acid carrier, insulin-like growth factor 1 (IGF-1) mutants were designed to prolong their plasma half-life, reduce the frequency of administration, and retain or improve efficacy.

Benefits of technology

It prolongs the half-life of IGF-1, reduces the risk of hypoglycemia, and improves therapeutic efficacy, especially in bronchopulmonary dysplasia and acute ischemic injury.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026096656_19112026_PF_FP_ABST
    Figure CN2026096656_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided in the present invention is an insulin-like growth factor (IGF-1) mutant polypeptide. An IGF‑1 fatty acid-modified derivative is obtained by means of conjugating IGF-1 or a mutant thereof with various fatty acid compounds. The derivative has long-acting properties and can reduce the risk of hypoglycemia. Further provided in the present invention is the use of the IGF-1 fatty acid-modified derivative in the treatment of primary IGF-1 deficiency or related diseases or disorders that can be ameliorated by IGF‑1.
Need to check novelty before this filing date? Find Prior Art

Description

An insulin-like growth factor (IGF-1) mutant and its fatty acid derivatives

[0001] Cross-references to related applications

[0002] This application claims priority to the following patent applications:

[0003] Priority is claimed for the earlier application filed with the State Intellectual Property Office of China on May 13, 2025, with patent application number 202510614513X and title "An Insulin-like Growth Factor (IGF-1) Mutant and Its Fatty Acid Derivative".

[0004] Priority is claimed for the earlier application filed with the State Intellectual Property Office of China on January 6, 2026, with patent application number 2026100096473 and title "An Insulin-like Growth Factor (IGF-1) Mutant and Its Fatty Acid Derivative".

[0005] Priority is claimed to the earlier application filed with the State Intellectual Property Office of China on May 11, 2026, with patent application number 2026106443222 and title "An Insulin-like Growth Factor (IGF-1) Mutant and Its Fatty Acid Derivative".

[0006] The entire contents of the aforementioned patent application are incorporated herein by reference. Technical Field

[0007] This invention relates to the field of biomedicine, and in particular to an insulin-like growth factor (IGF-1) mutant and its fatty acid derivatives, as well as their application in the treatment of IGF-1 deficiency-related diseases and diseases that can be improved by IGF-1. Background Technology

[0008] Insulin-like growth factor (IGF) is a polypeptide compound with a structure similar to insulin that promotes growth in the body. In humans, there are two types: IGF-1 (insulin-like growth factor-1) and IGF-2 (insulin-like growth factor-2). The IGF-1 polypeptide protein consists of 70 amino acids, contains three pairs of disulfide bonds, has a molecular weight of 7.6 kDa, and possesses four protein domains: B, C, A, and D. The B and A domains share 48% homology with the insulin sequence.

[0009] Under physiological conditions, IGF-1 is mainly synthesized and secreted by the liver (approximately 75%) under the stimulation of growth hormone secreted by the pituitary gland. It promotes cell proliferation and differentiation through endocrine, autocrine, and paracrine mechanisms, thereby regulating the growth and development of organs and tissues, such as promoting embryonic development and bone growth. The IGF-1R (IGF-1 receptor) on the cell surface is the main receptor for IGF-1. After binding to IGF-1, it undergoes dimerization, followed by autophosphorylation of the intracellular portion. Through a series of intracellular phosphorylation reactions, the signal is ultimately transduced into the cell nucleus, activating gene transcription to promote cell growth and proliferation.

[0010] In human serum, there exists an IGF-1 binding protein (IGFBP). This binding prolongs the circulating half-life of IGF-1. IGF-1, after binding to IGFBP-3 or IGFBP-5, can further bind to an acidic labile subunit (ALS) of a glycoprotein, forming a ternary complex. 75–80% of IGF-1 in serum exists in the form of a ternary complex; 20–25% of IGF-1 binds to other IGFBPs, existing in a binary complex. Less than 1% of IGF-1 exists in free form, with a half-life of less than 10 minutes. The binary complex increases the half-life of IGF-1 to approximately 25 minutes, and the ternary complex form of IGF-1 has a half-life exceeding 16 hours. The binary and ternary complexes not only increase the molecular weight of IGF-1 and reduce renal clearance, but also stabilize and protect IGF-1, reducing its degradation in serum, thus increasing the duration of IGF-1's action in vivo.

[0011] Primary IGF-1 deficiency is a rare endocrine disorder that manifests as short stature and growth retardation in children and adolescents. Laron syndrome is the classic form. Due to defects in the growth hormone receptor gene, post-receptor signaling, and IGF-1 synthesis, although the body's growth hormone levels may be normal or elevated, the body is insensitive to growth hormone, resulting in excessively low IGF-1 levels, thus affecting growth and development.

[0012] To date, the effective treatment for primary IGF-1 deficiency is replacement therapy with the recombinant IGF-1 drug mecasermin (brand name Increlex), which was approved as an orphan drug by the FDA in 2005 and by the EMEA in 2007. It has a half-life of 5.8 hours in humans and requires twice-daily subcutaneous injection. Hypoglycemia is the most significant side effect during treatment.

[0013] Bronchopulmonary dysplasia (BPD) is a common chronic respiratory disease in premature infants caused by a combination of factors. It increases the frequency of hospitalizations, the incidence of asthma and chest deformities. Severe BPD has a poor long-term prognosis and can leave respiratory sequelae. Currently, there are no clinically approved drugs, and existing preventive and treatment drugs are used off-label, with poor efficacy and some posing long-term safety risks. In preterm infants, serum IGF-1 concentration drops sharply to 10 ng / mL after birth, far below the intrauterine level of fetuses at the same gestational age (>50 ng / mL). The related drug OHB-607 is in phase II clinical trials. Although it has shown to significantly reduce the incidence of severe BPD, it requires continuous infusion for 24 hours due to its short half-life, and the central venous line is limited and prone to interruption. The final analysis of the phase II (Sections D) study showed that the incidence of severe BPD was lower in infants with IGF-1 reaching ≥70% of the target range and continuous infusion time ≥70% (only 39%) (4.8% of those who achieved the target with OHB-607 250 μg / kg / 24h, 21.3% in the same dose group, and 44.9% in the standard treatment group). Clinical data suggest that increasing drug exposure may further improve efficacy.

[0014] Apoptosis is the main cause of cell loss and infarct expansion in ischemic injuries such as acute ischemic stroke (AIS) and acute myocardial infarction (AMI). Hypoxia triggered by acute occlusion of nerves or coronary arteries initiates a biochemical cascade, leading to irreversible cell death. Current clinical treatments for AIS and AMI focus on vascular recanalization, but lack effective solutions for hypoxia-induced apoptosis and ischemia-reperfusion injury. IGF-1 can regulate anti-apoptotic and mitotic signaling pathways in various cells and is crucial for the development of organs such as the brain and heart. Studies have shown that it can reduce cell death after acute ischemic injury and promote functional recovery; plasma endogenous IGF-1 levels in AIS patients are positively correlated with prognosis. In animal models, the IGF-1 fusion protein scp776 can reduce stroke infarct volume and inhibit apoptosis in brain nerve cells and cardiomyocytes, and is currently in phase II clinical trials.

[0015] Therefore, it is necessary to develop novel IGF-1 drugs with longer half-lives and fewer side effects to address unmet clinical needs. Summary of the Invention

[0016] To address the industry-wide issue of the short half-life of IGF-1, this invention conjugates IGF-1 with a fatty acid carrier, thereby prolonging the plasma half-life of the IGF-1 protein and reducing the frequency of dosing. This invention provides the design and research of fatty acid-modified insulin-like growth factor (IGF-1) conjugates. By combining IGF-1 with various fatty acid compounds, this invention explores an IGF-1 drug that can achieve good efficacy while reducing the risk of hypoglycemia and decreasing the frequency of dosing.

[0017] I. Insulin-like growth factor 1 (IGF-1) mutant

[0018] In a first aspect, the present invention provides an insulin-like growth factor 1 (IGF-1) mutant, wherein, compared with the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, the mutant contains or contains only amino acid substitution mutations at one or more of the following positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9): position 20, position 27, position 29, position 50, position 55, position 59, position 64, position 65, and position 68;

[0019] Preferably, the mutant contains or contains only amino acid substitution mutations selected from one or more of the following positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9):

[0020] (i) The methionine at position 59 is mutated and replaced with any of the following amino acids: alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), leucine (M59L).

[0021] (ii) The aspartic acid at position 20 is mutated and replaced with lysine (D20K);

[0022] (iii) The lysine at position 27 is mutated to arginine (K27R);

[0023] (iv) The threonine at position 29 was mutated to lysine (T29K);

[0024] (v) The arginine at position 50 was mutated to lysine (R50K);

[0025] (vi) The arginine at position 55 is mutated and replaced with lysine (R55K);

[0026] (vii) The leucine at position 64 is mutated and replaced with lysine (L64K);

[0027] (viii) The lysine at position 65 is mutated to arginine (K65R) or serine (K65S);

[0028] (ix) The lysine at position 68 is mutated and replaced with arginine (K68R) or threonine (K68T);

[0029] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0030] As will be readily understood by those skilled in the art, the statement "each mutated amino acid site is a natural sequence site relative to the amino acid sequence shown in SEQ ID NO:1" means that the amino acid sites in the polypeptide are located at positions corresponding to the amino acid sites in the amino acid sequence shown in SEQ ID NO:1. For example, "position 1" means the amino acid site in the mutant that corresponds to position 1 of SEQ ID NO:1; "position 2" means the amino acid site in the mutant that corresponds to position 2 of SEQ ID NO:1.

[0031] As used herein, the expression "the amino acid site in the polypeptide that corresponds to the first amino acid residue of SEQ ID NO:1" means, when the sequence of the polypeptide is optimally aligned with SEQ ID NO:1, that is, when the sequence of the polypeptide is aligned with SEQ ID NO:1 to obtain the highest percentage identity, the amino acid site in the sequence of the polypeptide being compared is located at the same position as the first amino acid residue of SEQ ID NO:1.

[0032] Unless otherwise specified or there is a clear contradiction between the preceding and following statements, the meaning of the remaining similar expressions in this document shall be defined in a manner similar to that described above.

[0033] As used herein, the mutation “M59L” means that the methionine (M) residue at position 59 of SEQ ID NO:1 in the polypeptide is replaced with leucine (L); the mutation “D20K” means that the aspartic acid (D) residue at position 20 of SEQ ID NO:1 in the polypeptide is replaced with lysine (K).

[0034] Unless otherwise specified or there is a clear contradiction between the preceding and following statements, the meaning of the remaining similar expressions in this document shall be defined in a manner similar to that described above.

[0035] In some embodiments, the mutant is selected from any of the following compared to the amino acid sequence shown in SEQ ID NO:1:

[0036] (1) The mutant contains or contains only amino acid substitution mutations at the following two positions: position 65 and position 68;

[0037] Preferably, the mutant contains or contains only amino acid substitution mutations at the following two positions: K65R and K68R;

[0038] (2) The mutant contains or contains only three amino acid substitution mutations selected from the following positions: position 27, position 59, position 65, and position 68;

[0039] Preferably, the mutant contains or contains only three amino acid substitution mutations selected from the following positions: K27R, M59A or M59T or M59V or M59I or M59L, K65R or K65S, K68R or K68T;

[0040] (3) The mutant contains or contains only five amino acid substitution mutations selected from the following positions: position 20, position 27, position 29, position 50, position 55, position 59, position 64, position 65, and / or position 68;

[0041] Preferably, the mutant contains or contains only five amino acid substitution mutations selected from the following positions: D20K, K27R, T29K, R50K, R55K, M59L, L64K, K65R, K68R;

[0042] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0043] In some embodiments, the mutant, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, comprises or only comprises:

[0044] (1) It has an amino acid substitution mutation at least at position 59; preferably, the methionine at position 59 is mutated to alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), or leucine (M59L); and

[0045] (2) The mutant further comprises or contains only amino acid substitution mutations selected from one or more of the following positions (e.g., 1, 2, 3 or 4): position 20, position 27, position 29, position 50, position 55, position 64, position 65, position 68;

[0046] Preferably, the mutant further comprises or contains only amino acid substitution mutations selected from one or more of the following positions (e.g., 1, 2, 3, or 4): D20K, K27R, T29K, R50K, R55K, L64K, K65R or K65S, K68R or K68T.

[0047] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0048] In some embodiments, the mutant, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, comprises or only comprises:

[0049] (1) It has an amino acid substitution mutation at least at position 59; preferably, the methionine at position 59 is mutated to alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), or leucine (M59L); and

[0050] (2) The mutant further comprises any one of the following:

[0051] (i) The mutant further comprises or only comprises an amino acid substitution mutation selected from the following two positions: position 27, position 65, and position 68; preferably, the mutant further comprises an amino acid substitution mutation selected from the following two positions: K27R, K65R or K65S, K68R or K68T;

[0052] (ii) The mutant further comprises or contains only four amino acid substitution mutations selected from the following positions: position 20, position 27, position 29, position 50, position 55, position 64, position 65, and / or position 68;

[0053] Preferably, the mutant further comprises or contains only four amino acid substitution mutations selected from the following positions: D20K, K27R, T29K, R50K, R55K, L64K, K65R, K68R;

[0054] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0055] In some embodiments, the mutant, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, comprises or only comprises:

[0056] (1) There is an amino acid substitution mutation at least at position 59; preferably, the methionine at position 59 is substituted and mutated to alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), or leucine (M59L).

[0057] (2) There is an amino acid substitution mutation at least at position 65; preferably, the lysine at position 65 is mutated to arginine (K65R) or serine (K65S);

[0058] (3) There is an amino acid substitution mutation at least at position 68; preferably, the lysine at position 68 is mutated to arginine (K68R) or threonine (K68T);

[0059] And optional location,

[0060] (4) The mutant further comprises or only comprises amino acid substitution mutations selected from one or more of the following positions (e.g., 2): position 20, position 27, position 29, position 50, position 55, position 64;

[0061] Preferably, the mutant further comprises or only comprises amino acid substitution mutations selected from one or more of the following positions (e.g., two): D20K, K27R, T29K, R50K, R55K, L64K;

[0062] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0063] In some embodiments, the mutant, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, comprises or only comprises:

[0064] (1) There is an amino acid substitution mutation at least at position 59; preferably, the methionine at position 59 is substituted and mutated to leucine (M59L);

[0065] (2) There is an amino acid substitution mutation at least at position 65; preferably, the lysine at position 65 is mutated to arginine (K65R);

[0066] (3) It has an amino acid substitution mutation at least at position 68; preferably, the lysine at position 68 is mutated to arginine (K68R); and

[0067] (4) The mutant further comprises an amino acid substitution mutation selected from the following two positions: position 20, position 27, position 29, position 50, position 55, and position 64;

[0068] Preferably, the mutant further comprises or only comprises an amino acid substitution mutation selected from the following two positions: D20K, K27R, T29K, R50K, R55K, L64K;

[0069] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0070] In some embodiments, the mutant, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, comprises or only comprises:

[0071] (1) There is an amino acid substitution mutation at least at position 59; preferably, the methionine at position 59 is substituted and mutated to alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), or leucine (M59L).

[0072] (2) There is an amino acid substitution mutation at least at position 65; preferably, the lysine at position 65 is mutated to arginine (K65R) or serine (K65S);

[0073] (3) There is an amino acid substitution mutation at least at position 68; preferably, the lysine at position 68 is mutated to arginine (K68R) or threonine (K68T);

[0074] (4) There is an amino acid substitution mutation at least at position 27; preferably, the lysine at position 27 is mutated to arginine (K27R);

[0075] And optional location,

[0076] (5) The mutant further comprises or only comprises an amino acid substitution mutation selected from one or more of the following positions (e.g., 1): position 20, position 29, position 50, position 55, position 64;

[0077] Preferably, the mutant further comprises or contains only amino acid substitution mutations selected from one or more of the following positions (e.g., 1): D20K, T29K, R50K, R55K, L64K;

[0078] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0079] In some embodiments, the mutant, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, comprises or only comprises:

[0080] (1) There is an amino acid substitution mutation at least at position 59; preferably, the methionine at position 59 is substituted and mutated to leucine (M59L);

[0081] (2) There is an amino acid substitution mutation at least at position 65; preferably, the lysine at position 65 is mutated to arginine (K65R);

[0082] (3) There is an amino acid substitution mutation at least at position 68; preferably, the lysine at position 68 is mutated to arginine (K68R);

[0083] (4) There is an amino acid substitution mutation at at least position 27; preferably, the lysine at position 27 is mutated to arginine (K27R); and

[0084] (5) The mutant further comprises or only comprises an amino acid substitution mutation selected from one of the following positions: position 20, position 29, position 50, position 55, position 64;

[0085] Preferably, the mutant further comprises or contains only amino acid substitution mutations selected from one or more of the following positions (e.g., 1): D20K, T29K, R50K, R55K, L64K;

[0086] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0087] In some embodiments, compared with the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, the mutant contains or only contains amino acid substitution mutations selected from any combination of the following positions: positions 65 and 68; positions 59, 65, and 68; positions 59, 65, and 68; positions 27, 29, 59, 65, and 68; positions 20, 27, 59, 65, and 68; positions 27, 50, 59, 65, and 68; positions 27, 55, 59, 65, and 68; positions 27, 64, 59, 65, and 68; positions 27, 59, and 68.

[0088] In some embodiments, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, the mutant is selected from any combination of the following amino acid substitution mutations:

[0089] (i)K65R, K68R;

[0090] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0091] As used herein, the mutations “K65R, K68R” mean that the amino acid residue K at position 65 of SEQ ID NO:1 is replaced with R, and the amino acid residue K at position 68 of SEQ ID NO:1 is replaced with R.

[0092] Unless otherwise specified or there is a clear contradiction between the preceding and following statements, the meaning of the remaining similar expressions in this document shall be defined in a manner similar to that described above.

[0093] In some embodiments, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, the mutant is selected from any combination of the following amino acid substitution mutations:

[0094] (i)M59A, K65R, K68R;

[0095] (ii)M59T, K65R, K68R;

[0096] (iii) M59V, K65R, K68R;

[0097] (iv)M59I, K65R, K68R;

[0098] (v)M59L, K65R, K68R;

[0099] (vi)K27R, M59L, K68R;

[0100] (vii)M59L, K65S, K68T;

[0101] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0102] In some embodiments, compared to the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, the mutant is selected from any combination of the following amino acid substitution mutations:

[0103] (i)K27R, T29K, M59L, K65R, K68R;

[0104] (ii)D20K, K27R, M59L, K65R, K68R;

[0105] (iii)K27R, R50K, M59L, K65R, K68R;

[0106] (iv)K27R, R55K, M59L, K65R, K68R;

[0107] (v)K27R, L64K, M59L, K65R, K68R;

[0108] The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:1.

[0109] In some embodiments, the mutant comprises an amino acid sequence as shown in any one of SEQ ID NOs:2-14, or an amino acid sequence having at least 90%, for example at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs:2-14.

[0110] Secondly, the present invention also provides isolated nucleic acid molecules that encode the mutants described in the first aspect.

[0111] Thirdly, the present invention also provides a carrier comprising the isolated nucleic acid molecules described in the second aspect.

[0112] Fourthly, the present invention also provides a host cell comprising the isolated nucleic acid molecule described in the second aspect or the vector described in the third aspect.

[0113] Fifthly, the present invention also provides a method for preparing the mutant described in the first aspect, comprising culturing the host cell of the fourth aspect under conditions that allow expression of the mutant, and recovering the mutant from the cultured host cell culture.

[0114] II. Fatty acid derivatives of insulin-like growth factor 1 (IGF-1)

[0115] In a sixth aspect, the present invention also provides an insulin-like growth factor 1 (IGF-1) fatty acid derivative or a pharmaceutical salt thereof, comprising an insulin-like growth factor 1 (IGF-1) mutant and a fatty acid; wherein the fatty acid is directly or via a linker linked to the insulin-like growth factor 1 (IGF-1) mutant.

[0116] In some embodiments, the present invention provides an insulin-like growth factor 1 (IGF-1) fatty acid derivative or a pharmaceutical salt thereof, comprising an insulin-like growth factor 1 (IGF-1) mutant and a fatty acid; wherein the fatty acid is linked to the insulin-like growth factor 1 (IGF-1) mutant via a linker, wherein the fatty acid-linker fragment is selected from one or more structures shown in Z1, Z2, Z3 or Z4:

[0117] In some embodiments, the insulin-like growth factor 1 (IGF-1) mutant is the peptide chain residue backbone of the mutant described in the first aspect of the present invention.

[0118] In some embodiments, an insulin-like growth factor 1 (IGF-1) fatty acid derivative or a pharmaceutical salt thereof of the present invention is represented by the following general formula: P-(LA) n ;in,

[0119] P represents insulin-like growth factor 1 (IGF-1) or its mutant, L represents a linker, A represents a fatty acid, and n is an integer from 1 to 5, preferably an integer from 1 to 4.

[0120] In some implementations, P is selected from the peptide chain residue backbone of wild-type IGF-1 or the mutant described in the first aspect.

[0121] In some implementations, L is selected from -(OEG). m1 -(γGlu) m2 -,in,

[0122] (OEG) represents -CO-(CH2)-O-(CH2)2-O-(CH2)2-NH-, where the -CO- end is connected to P.

[0123] (γGlu) represents In this configuration, terminal 1 is connected to the -NH- end of (OEG) or to P, and terminal 2 is connected to the -CO- end of A.

[0124] m1 is an integer from 0 to 5, preferably an integer from 0 to 2.

[0125] m2 is an integer from 1 to 4, preferably an integer from 1 to 2.

[0126] In some implementations, A is selected from -CO(CH2). p COOH, p is an integer from 14 to 22, preferably an integer from 16 to 18, more preferably 16 or 18.

[0127] In some implementations, -(LA) is selected from the structures shown in formulas Z1, Z2, Z3, or Z4:

[0128] In some embodiments, the IGF-1 fatty acid derivative or its pharmaceutical salt thereof, wherein the fatty acid A is coupled to P via linker L at a site that is a lysine residue or a glycine residue in insulin-like growth factor 1 (IGF-1) or its mutant.

[0129] In some embodiments, the fatty acid A is coupled to P via linker L at an ε-side chain group of a lysine residue or an α-side chain group of a glycine residue in insulin-like growth factor 1 (IGF-1) or its mutant.

[0130] In some embodiments, the fatty acid A is coupled to P via linker L at an amino group of the ε side chain of a lysine residue in the IGF-1 or its mutant, and / or an amino group of the α side chain of a glycine residue in the IGF-1 or its mutant.

[0131] In some embodiments, the fatty acid A is coupled to P via linker L at an amino group of the ε side chain of lysine residues at all positions in the IGF-1 or its mutants, and / or, the amino group of the α side chain of the glycine residue at position 1.

[0132] In some embodiments, the fatty acid A is coupled to P via linker L at an amino group of the ε side chain of lysine residues at all positions in the IGF-1 or its mutants.

[0133] In some embodiments, the fatty acid A is coupled to P via linker L at the amino group of the ε side chain of lysine residues at all positions in the IGF-1 or its mutants, and the amino group of the α side chain of the glycine residue at position 1.

[0134] In some embodiments, the site where fatty acid A is coupled to P via linker L is in IGF-1 or a mutant thereof:

[0135] (i) The amino group of the ε side chain of the 27th lysine residue, the 65th lysine residue, and the 68th lysine residue of the wild-type IGF-1.

[0136] (ii) The amino group of the α side chain of the glycine residue at position 1, the amino group of the ε side chain of the lysine residue at position 27, the amino group of the ε side chain of the lysine residue at position 65, and the amino group of the ε side chain of the lysine residue at position 68 of the wild-type IGF-1.

[0137] (iii) The amino group of the ε side chain of the 27th lysine residue in the IGF-1 mutant;

[0138] (iv) The amino group of the α-side chain of the glycine residue at position 1 and the amino group of the ε-side chain of the lysine residue at position 27 of the IGF-1 mutant.

[0139] (v) The amino group of the ε side chain of the 65th lysine residue in the IGF-1 mutant;

[0140] (vi) The amino group of the α side chain of the glycine residue at position 1 and the amino group of the ε side chain of the lysine residue at position 65 of the IGF-1 mutant.

[0141] (vii) The amino group of the ε side chain of the 29th lysine residue in the IGF-1 mutant;

[0142] (viii) The amino group of the α side chain of the glycine residue at position 1 and the amino group of the ε side chain of the lysine residue at position 29 of the IGF-1 mutant.

[0143] (ix) The amino group of the ε side chain of the 20th lysine residue in the IGF-1 mutant;

[0144] (x) The amino group of the α-side chain of the glycine residue at position 1 and the amino group of the ε-side chain of the lysine residue at position 20 of the IGF-1 mutant.

[0145] (xi) The amino group of the ε side chain of the 50th lysine residue in the IGF-1 mutant;

[0146] (xii) The amino group of the α side chain of the glycine residue at position 1 and the amino group of the ε side chain of the lysine residue at position 50 of the IGF-1 mutant.

[0147] (xiii) The amino group of the ε side chain of the 55th lysine residue in the IGF-1 mutant;

[0148] (xiv) The amino group of the α side chain of the glycine residue at position 1 and the amino group of the ε side chain of the lysine residue at position 55 of the IGF-1 mutant.

[0149] (xv) The amino group of the ε-side chain of the 64th lysine residue in the IGF-1 mutant; or

[0150] (xvi) The amino group of the α-side chain of the glycine residue at position 1 and the amino group of the ε-side chain of the lysine residue at position 64 of the IGF-1 mutant.

[0151] In some embodiments, the IGF-1 fatty acid derivative comprises an amino acid sequence as shown in any one of SEQ ID NOs: 15-31, or an amino acid sequence having at least 90%, for example at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 15-31.

[0152] In some embodiments, the IGF-1 fatty acid derivatives are selected from C-P1370011, C-P1370009, C-P1370001, C-P1370002, C-P1370003, C-P1370004, C-P1370010, C-24B0320003, C-24B0320004, C-24B0320007, C-24B0320013, C-24B0320015, C-24B0320016, C-24B0320017, C-24B0320018, C-24B0320019, and C-24B0320038 as described in Table 2.

[0153] In some embodiments, the IGF-1 fatty acid derivative comprises an amino acid sequence as shown in any one of SEQ ID NOs: 15-24, or an amino acid sequence having at least 90%, for example at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs: 15-24.

[0154] In some embodiments, the IGF-1 fatty acid derivatives are selected from C-P1370011, C-P1370009, C-P1370001, C-P1370002, C-P1370003, C-P1370004, C-P1370010, C-24B0320003, C-24B0320004, and C-24B0320007 as described in Table 2.

[0155] In some implementations, IGF-1 fatty acid derivatives retain the full functional activity of wild-type IGF-1 products and provide an extended in vivo half-life compared to wild-type IGF-1.

[0156] In some embodiments, the IGF-1 fatty acid derivatives retain at least 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, or 150 percent (%) of biological activity relative to wild-type IGF-1.

[0157] In some implementations, the bioactivity of wild-type IGF-1, IGF-1 mutants, IGF-1 fatty acid derivatives or their pharmaceutical salts is determined, for example, by phosphorylation activity of Akt, a downstream signaling pathway molecule of the IGF-1 receptor, and proliferation activity of MCF-7 cells.

[0158] In some embodiments of the present invention, the half-life of the IGF-1 fatty acid derivative is increased by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times relative to the in vivo half-life of wild-type IGF-1.

[0159] As used herein, “IGF-1 or a variant thereof” means wild-type IGF-1 (e.g., wild-type human IGF-1) or an IGF-1 mutant (e.g., the IGF-1 mutant described in the first aspect of the invention).

[0160] As used in this article, “IGF-1 fatty acid derivatives,” “IGF-1 fatty acid derivatives,” “fatty acid-modified IGF-1 conjugates,” and “fatty acid-modified IGF-1 molecules” all refer to IGF-1 or its variants covalently linked to one or more fatty acid compounds through an amino reactive coupling of one or more lysine or glycine residues of IGF-1 or its variants.

[0161] In a seventh aspect, the present invention also provides a method for preparing the IGF-1 fatty acid derivative or pharmaceutical salt thereof as described in the sixth aspect, the method comprising reacting the IGF-1 or a mutant thereof with the fatty acid under certain conditions, the conditions being such that the fatty acid is chemically bound to the amino group of the IGF-1 or the mutant thereof.

[0162] III. Pharmaceutical Composition

[0163] In an eighth aspect, the present invention also provides a pharmaceutical composition comprising the IGF-1 mutant described in the first aspect or the IGF-1 fatty acid derivative described in the sixth aspect or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and / or excipient.

[0164] The IGF-1 mutants, IGF-1 fatty acid derivatives, or pharmaceutical compositions comprising them of the present invention can be formulated into any dosage form known in the medical field, such as tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injection solutions, sterile powders for injection, and concentrated solutions for injection), inhalers, sprays, etc. Preferred dosage forms depend on the intended route of administration and therapeutic use. The IGF-1 mutants, IGF-1 fatty acid derivatives, or pharmaceutical compositions comprising them of the present invention should be sterile and stable under the conditions of manufacture and storage.

[0165] The IGF-1 mutants, IGF-1 fatty acid derivatives, or pharmaceutical compositions comprising them of the present invention may be administered by any suitable method known in the art, including but not limited to oral, oral, sublingual, ocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum groove, groin, bladder, topical (e.g., powder, ointment, or drops), or nasal routes. However, for many therapeutic uses, the preferred route / method of administration is parenteral administration (e.g., intravenous injection or bolus, subcutaneous injection, intraperitoneal injection, intramuscular injection). Those skilled in the art will understand that the route and / or method of administration will vary depending on the intended purpose. In some embodiments, the IGF-1 mutants, IGF-1 fatty acid derivatives, or pharmaceutical compositions comprising them of the present invention are administered by intravenous injection or bolus.

[0166] The IGF-1 mutants, IGF-1 fatty acid derivatives, or pharmaceutical compositions comprising them of the present invention can be formulated in dosing units for easy administration. Dosing unit form refers to physically discrete units suitable for use as a single dose in a subject to be treated; each unit contains a predetermined amount of the active ingredient calculated to produce the desired therapeutic effect when combined with a desired drug carrier.

[0167] In some embodiments, the IGF-1 mutants, IGF-1 fatty acid derivatives, or pharmaceutical compositions comprising them of the present invention may be administered alone or in combination with other pharmaceutically active agents (e.g., agents that promote growth) or other therapies.

[0168] IV. Uses or Treatments

[0169] In a ninth aspect, the present invention provides the use of the IGF-1 mutant described in the first aspect, the IGF-1 fatty acid derivative described in any of the sixth aspects or a pharmaceutical salt thereof, or the pharmaceutical composition described in the eighth aspect for therapeutic purposes.

[0170] In a tenth aspect, the present invention provides the use of the IGF-1 mutant described in the first aspect, the IGF-1 fatty acid derivative described in any of the sixth aspects or a pharmaceutical salt thereof, or the pharmaceutical composition described in the eighth aspect for use as a medical medicament.

[0171] In an eleventh aspect, the present invention also provides the use of the IGF-1 mutant described in the first aspect, the IGF-1 fatty acid derivative described in any of the sixth aspects or a pharmaceutical salt thereof, or the pharmaceutical composition described in the eighth aspect in the preparation of a medicament for treating primary IGF-1 deficiency or for IGF-1 to improve the disease.

[0172] In a twelfth aspect, the present invention also provides a method for treating primary IGF-1 deficiency, wherein IGF-1 can improve the disease, comprising administering to a subject in need an effective amount of the IGF-1 mutant described in the first aspect, the IGF-1 fatty acid derivative described in the sixth aspect or a pharmaceutical salt thereof, or the pharmaceutical composition described in the eighth aspect.

[0173] In some implementations, the diseases or conditions include, but are not limited to: growth and development disorders caused by primary IGF-1 deficiency, such as short stature, growth retardation, skeletal dysplasia, muscular dysplasia, facial and body feature abnormalities, and other systemic developmental disorders, growth hormone insensitivity syndrome (GHIS), and growth disorders caused by growth hormone receptor defects (i.e., Laron syndrome); IGF-1 can improve diseases such as bronchopulmonary dysplasia (BPD) in premature infants, retinopathy of prematurity (ROP) in premature infants, brain injury in premature infants (including germinal matrix, intraventricular hemorrhage and intraventricular hemorrhage (GM-IVH), periventricular hemorrhagic infarction (PVHI), and white matter injury (WMI) in premature infants), and acute myocardial infarction (AMI). Myocardial infarction (AMI), stroke, acute ischemic stroke (AIS), cerebral infarction, improvement of neurological deficits in patients with acute ischemic stroke or stroke, diabetes, neurodegenerative diseases, cartilage repair, deafness, autism.

[0174] The subjects mentioned in this article may be mammals, such as humans.

[0175] The patients treated by this invention include, but are not limited to: patients with severe primary insulin-like growth factor-1 deficiency (sPIGFD), extremely preterm infants (EPI), and patients with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).

[0176] In a thirteenth aspect, the present invention also provides the use of the IGF-1 mutant described in the first aspect, the IGF-1 fatty acid derivative described in any of the sixth aspects, or the pharmaceutical composition described in the eighth aspect in the preparation of a medicament for treating diseases caused by external trauma or intrinsic causes, such as vascular occlusion, vascular rupture, brain nerve cell damage, and neurodegenerative diseases.

[0177] Preferably, the diseases caused by vascular occlusion, vascular rupture, and brain nerve cell damage include: acute myocardial infarction, acute ischemic stroke (AIS), cerebral stroke, acute ischemic stroke, hemorrhagic stroke, traumatic brain injury (TBI), autism, and amyotrophic lateral sclerosis (ALS).

[0178] In a fourteenth aspect, the present invention also provides the use of the IGF-1 mutant described in the first aspect, the IGF-1 fatty acid derivative described in any of the sixth aspects, or the pharmaceutical composition described in the eighth aspect in the treatment of medicaments for the preparation of developmental diseases of preterm infants or perinatal injury diseases.

[0179] Preferably, the developmental diseases or perinatal injury diseases of premature infants include bronchopulmonary dysplasia (BPD) and related diseases;

[0180] Preferably, the BPD-related diseases include: growth retardation in premature infants, intellectual disability in premature infants, death in premature infants, bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH), retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH) in premature infants, including white matter injury (WMI) or periventricular leukomalacia (PVL) in premature infants, necrotizing enterocolitis (NEC), cardiopulmonary insufficiency and growth retardation caused by BPD.

[0181] V. Terminology Definition

[0182] In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the virological, biochemical, and immunological laboratory procedures used herein are all standard procedures widely used in their respective fields. To better understand this invention, definitions and explanations of relevant terms are provided below.

[0183] When the terms “for example,” “such as,” “like,” “including,” “contains,” or variations thereof are used herein, these terms will not be considered restrictive terms but will be interpreted as meaning “but not limited to” or “not limited to.”

[0184] As used herein, the term “contains only” will be interpreted as meaning “limited to” but not including any scope beyond that.

[0185] Unless otherwise specified herein or clearly contradicted by the context, the terms “an” and “a kind” as well as “the” and similar designations shall be interpreted to cover both the singular and the plural in the context of describing the invention (especially in the context of the following claims).

[0186] As used herein, the term "identity" refers to the sequence matching between two polypeptides or two nucleic acids. To determine the percentage identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., a gap may be introduced in the first amino acid sequence or nucleic acid sequence to best align with the second amino acid sequence or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecule is identical at that position. The percentage identity between two sequences is a function of the number of identity positions shared by the sequences (i.e., percentage identity = number of identical overlapping positions / total number of positions × 100%). In some embodiments, the two sequences are of the same length.

[0187] The determination of percentage identity between two sequences can also be achieved using mathematical algorithms. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, as an improvement upon that in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such algorithms are integrated into the NBLAST and XBLAST procedures of Altschul et al., 1990, J. Mol. Biol. 215:403.

[0188] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between a ligand and its targeted receptor. The strength or affinity of a specific binding interaction can be expressed by the equilibrium dissociation constant (KD) of that interaction. In this invention, the term "KD" refers to the dissociation equilibrium constant of a specific ligand-receptor interaction, which is used to describe the binding affinity between the ligand and the receptor. The smaller the equilibrium dissociation constant, the stronger the ligand-receptor binding and the higher the affinity between the ligand and the receptor.

[0189] The specific binding properties between two molecules can be determined using methods known in the art. One method involves measuring the rates of ligand / receptor complex formation and dissociation. Both the “binding rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and the actual rates of association and dissociation (see Malmqvist M, Nature, 1993, 361:186-187). The ratio of kdis / kon is equal to the dissociation constant KD (see Davies et al., Annual Rev Biochem, 1990; 59:439-473). The values ​​of KD, kon, and kdis can be measured using any effective method; for example, the dissociation constant can be measured using surface plasmon resonance (SPR) in Biacore, or using bioluminescent interferometry or Kinexa.

[0190] The twenty common amino acids mentioned in this article are written in accordance with conventional usage. See, for example, Immunology-A Synthesis (2nd Edition, E.S. Golub and D.G. Ren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In this invention, the terms “polypeptide” and “protein” have the same meaning and are used interchangeably. Furthermore, in this invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0191] As used herein, the term "derivative" refers to a compound that is structurally substantially similar to, and has the same biological activity as, a naturally occurring molecule (although differing to some extent in some cases). For example, a "derivative" is a modified (e.g., chemically modified) polypeptide that shares the same or substantially similar structure as a reference polypeptide.

[0192] As used herein, the term "mutant" is a compound that is structurally substantially similar to and has the same biological activity as a naturally occurring molecule (although differing to some extent in some cases). For example, a peptide mutant is a peptide that shares a substantially similar structure with a reference peptide and has the same biological activity. A mutant differs from a naturally occurring peptide from which it is derived based on one or more mutations involving: (i) the deletion of one or more amino acid residues at one or more ends of the peptide and / or one or more internal regions of the naturally occurring peptide sequence (e.g., fragments); (ii) the insertion or addition of one or more amino acids at one or more ends of the peptide (typically "addition" or "fusion") and / or one or more internal regions of the naturally occurring peptide sequence (typically "insertion"); or (iii) the substitution of one or more amino acids in other amino acids in the naturally occurring peptide sequence.

[0193] In substitution mutants, one or more amino acid residues of the therapeutic protein polypeptide are removed and replaced by substituted residues. In one aspect, the substitution is conserved in nature and this type of conserved substitution is well known in the art. Alternatively, the invention covers substitutions that are also non-conservative. Exemplary conserved substitutions are described in Lehninger, [Biochemistry, 2nd ed.; Worth Publishers, Inc., New York (1975), pp. 71-77].

[0194] In various embodiments, the derivative or mutant is designed to allow, for example, the coupling of another molecule to the protein mutant or derivative, thereby forming the coupled protein of the present invention.

[0195] As used herein, the term “IGF-1 fatty acid derivative” is equivalent to the terms “IGF-1 fatty acid derivative”, “fatty acid-modified insulin-like growth factor (IGF-1) conjugate”, “fatty acid-modified IGF-1 conjugate”, or “fatty acid-modified IGF-1”.

[0196] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which polynucleotides can be inserted. When a vector enables the expression of a protein encoded by the inserted polynucleotide, it is called an expression vector. Vectors can be introduced into host cells through transformation, transduction, or transfection, allowing the genetic material elements they carry to be expressed in the host cells. Vectors are well-known to those skilled in the art and include, but are not limited to: plasmids; phage particles; Cos plasmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC); bacteriophages such as λ phage or M13 phage; and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retrotranscriptoviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomaviruses (such as SV40). A vector may contain multiple elements controlling expression, including but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain a replication initiation site.

[0197] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells, or human cells.

[0198] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" means a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, and is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995).

[0199] As used herein, the term "treatment" refers to a method performed to obtain a beneficial or desired clinical outcome. For the purposes of this invention, a beneficial or desired clinical outcome includes (but is not limited to) alleviating symptoms, reducing the extent of disease, stabilizing (i.e., no longer worsening) the state of disease, delaying or slowing the progression of disease, improving or alleviating the state of disease, and relieving symptoms (whether partial or complete), whether detectable or undetectable. Furthermore, "treatment" can also refer to prolonging survival compared to the expected survival (if no treatment had been received). The term "therapeuticly effective amount" refers to the amount of an active compound or drug that researchers, veterinarians, physicians, or other clinicians are searching for in tissues, systems, animals, individuals, or humans to elicit a biological or medical response.

[0200] As used herein, the term "subject" refers to a mammal, such as a mouse, rat, other rodent, rabbit, dog, cat, pig, cow, sheep, horse, or primate, such as a human. In some embodiments, the subject (e.g., a human) suffers from primary IGF-1 deficiency.

[0201] As used in this article, the terms "premature" and "preterm infant" refer to newborns born before 37 weeks of gestation (gestational age <37 weeks). Premature birth carries a high risk of complications and death, especially for extremely preterm infants (VPI, gestational age <32 weeks) and very preterm infants (EPI, gestational age <28 weeks). Low birth weight (LBW) refers to newborns with a birth weight <2500g, primarily composed of premature infants, and represents a high-risk group for neonatal complications and death.

[0202] VI. Beneficial Effects of the Invention

[0203] Compared with existing technologies, the IGF-1 mutant and its fatty acid derivatives of the present invention have the following advantages:

[0204] 1. This invention provides a long-acting IGF-1 fatty acid derivative, which has a higher dosing frequency than the existing recombinant IGF-1 protein peptide drug Increlex.

[0205] 2. In animal models, the molecule of the present invention has better glycemic safety than the reference drug Increlex, with more stable glycemic fluctuations and a higher tolerable dose.

[0206] 3. In animal models, the molecules of the present invention have a longer in vivo half-life than Increlex.

[0207] 4. The molecules of the present invention have the potential to reduce the frequency of clinical administration.

[0208] 5. The indications for treatment with this invention include, but are not limited to, primary IGF-1 deficiency and diseases that can be improved by IGF-1; specifically: growth and development disorders caused by primary IGF-1 deficiency, such as short stature, growth retardation, skeletal developmental abnormalities, muscular system dysplasia, facial and body feature abnormalities, and other systemic developmental disorders, growth hormone insensitivity syndrome (GHIS), and growth disorders caused by growth hormone receptor defects (i.e., Laron syndrome); diseases that can be improved by IGF-1, such as bronchopulmonary dysplasia (BPD) in premature infants, retinopathy of prematurity (ROP) in premature infants, and brain injury in premature infants (including germinal matrix hemorrhage and intraventricular hemorrhage, GM-IVH, and periventricular hemorrhagic infarction). Infarction, PVHI, white matter injury (WMI), acute myocardial infarction (AMI), stroke, acute ischemic stroke (AIS), cerebral infarction, improvement of neurological deficits in stroke patients, diabetes, neurodegenerative diseases, cartilage repair, deafness, autism.

[0209] 6. Patients treated by this invention include, but are not limited to: patients with severe primary insulin-like growth factor-1 deficiency (sPIGFD), extremely preterm infants (EPI), and patients with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT). Attached Figure Description

[0210] Figures 1A-1B: Detection results of AKT phosphorylation signaling activation activity of IGF-1 mutants at the cellular level. Figure 1A: Detection results of P-P1370110, P-24B0320003, P-24B0320004, and P-24B0320007. Figure 1B: Detection results of P-24B0320013, P-24B0320015 to C-24B0320019, and P-24B0320038.

[0211] Figures 2A-2F: Cellular-level AKT phosphorylation activation activity of fatty acid-modified IGF-1 conjugates and the effect of albumin on their activity. Figure 2A: C-P1370001; Figure 2B: C-P1370002; Figure 2C: C-P1370003; Figure 2D: C-P1370004; Figure 2E: C-P1370010; Figure 2F: C-P1370009 and C-P1370011.

[0212] Figure 3A-3C: AKT phosphorylation activation activity results of fatty acid-modified IGF-1 conjugates at the cellular level. Figure 3A: AKT phosphorylation activation activity results of C-P1370010, C-24B0320003, C-24B0320004, and C-24B0320007 at the cellular level. Figure 3B: Effect of albumin on the AKT phosphorylation signaling activation activity of fatty acid-modified IGF-1 conjugate C-24B0320007. Figure 3C: AKT phosphorylation activation activity results of fatty acid-modified IGF-1 conjugates C-24B0320013, C-24B0320015 to C-24B0320019, and C-24B0320038 at the cellular level.

[0213] Figure 4: Results of the assay for the promoting activity of fatty acid-modified IGF-1 conjugate C-24B0320007 on MCF cell proliferation and the effect of albumin on its activity.

[0214] Figure 5: Results of the activity of fatty acid-modified IGF-1 conjugates C-P1370002, C-P1370009, C-P1370010, and C-P1370011 in promoting body weight gain in a C57 mouse model. (G1, G2, G3, G6, G8, G10, and G12 represent the names of each group).

[0215] Figure 6: Effects of different doses of C-P1370010 on blood glucose levels in wild-type mice.

[0216] Figure 7A: Results of blood glucose level detection in GHR gene knockout mice using the positive control drug (PC, Increlex). Figure 7B: Results of blood glucose level detection in GHR gene knockout mice using dose groups A-E of the test sample (C-24B0320007).

[0217] Figures 8A-8D: Pharmacodynamic results of fatty acid-modified IGF-1 conjugate C-24B0320007 in GHR gene knockout mouse model. Figure 8A: Results of weight changes in GHR gene knockout mice under dose groups A, B, C, D, E, and F of the test sample (C-24B0320007). Figure 8B: Results of body and tail length changes in GHR gene knockout mice under dose groups A, B, C, D, E, and F of the test sample (C-24B0320007). Figure 8C: Results of tibial length in GHR gene knockout mice under dose groups A, B, C, D, E, and F of the test sample (C-24B0320007). Figure 8D: Results of epiphyseal plate thickness in GHR gene knockout mice under dose groups A, B, C, D, E, and F of the test sample (C-24B0320007).

[0218] Figures 9A-9D: Pharmacodynamic results of fatty acid-modified IGF-1 conjugate C-24B0320007 in a hypophysectomized rat model. Figure 9A: Results of the test sample on blood glucose levels in hypophysectomized rats. Figure 9B: Results of the test sample on weight changes in hypophysectomized rats. Figure 9C: Results of the test sample on epiphyseal plate thickness in hypophysectomized rats. Figure 9D: Results of the test sample on tibial length in hypophysectomized rats.

[0219] Figure 10: PK test results in mice after a single dose of C-P1370010.

[0220] Figure 11: PK test results in rats after a single dose of C-P1370010.

[0221] Figure 12: PK test results in dogs after a single dose of C-P1370010.

[0222] Figure 13A: PK detection results in GHR gene knockout mice after subcutaneous administration of C-24B0320007. Figure 13B: PK detection results in hypophysectomized (HPO) rats after subcutaneous administration of C-24B0320007. Figure 13C: PK detection results in dogs after a single dose of C-24B0320007 and increlex.

[0223] Figure 14: Protective effect of C-24B0320007 against H2O2-induced SH-SY5Y oxidative stress cell damage.

[0224] Figure 15: Improvement of cerebral infarction rate in a rat model of ischemic stroke caused by the middle cerebral artery by C-24B0320007.

[0225] Figure 16: Effect of C-24B0320007 on the endothelial cells of human umbilical vein.

[0226] Figure 17: Results of data analysis on tube formation of human umbilical vein endothelial cells using C-24B0320007.

[0227] Figure 18: Effect of C-24B0320007 on the mean alveolar number in the lung tissue of hyperoxia-induced neonatal rats with BPD.

[0228] Figure 19: Effect of C-24B0320007 on the number of radial alveoli in the lung tissue of hyperoxia-induced neonatal rats with BPD.

[0229] Figure 20: Effect of C-24B0320007 on the mean alveolar lining septum of lung tissue in hyperoxia-induced BPD in newborn rats.

[0230] Figure 21: Effect of C-24B0320007 on microvascular density in lung tissue of hyperoxia-induced BPD in newborn rats.

[0231] sequence list

[0232] Table 1: Sequence listing of IGF-1 mutants

[0233] Table 2: Sequence information of IGF-1 fatty acid derivatives:

[0234] In this application, the symbol “{}” is used to represent an amino acid as a whole, and the “()” in the symbol “{}” is used to represent the modifying group of the amino acid represented by a single letter or three letters within the symbol “{}”, for example, {G(ɑ-Z2)} represents the amino group at the ɑ position being -OEG-γGlu-CO(CH2). 16 COOH-modified Gly, {K(ε-Z4)} indicates that the amino group at the ε position is modified by -γGlu-CO(CH2). 16 COOH-modified Lys, where the amino group on the side chain is replaced by -γGlu-CO(CH2). 16 COOH-modified Lys Detailed Implementation

[0235] The invention will now be described with reference to the following embodiments, which are intended to illustrate the invention (and not limit it). Those skilled in the art will appreciate that the embodiments are described by way of example and are not intended to limit the scope of protection claimed by the invention.

[0236] The intermediates used in the preparation of the IGF-1 fatty acid derivatives of this invention can all be prepared using conventional synthetic methods known in the art, or obtained directly through commercial channels.

[0237] Example 1: Design and preparation of IGF-1 mutant protein

[0238] Example 1.1: Design and preparation of IGF-1 mutant protein

[0239] The methionine at position 59 of IGF-1 contains a sulfur atom in its side chain, making it highly susceptible to oxidation. The resulting sulfoxide or sulfone groups have different steric hindrances and electronic properties, altering the protein conformation and interfering with IGF-1 binding to its receptor. Furthermore, methionine oxidation produces impurities that can mix with unoxidized IGF-1, increasing the difficulty of separation and purification. To address the problem of the highly oxidizable methionine at position 59 during IGF-1 production and fatty acid coupling, this invention designs mutations in the A, T, V, I, and L positions of methionine at position 59.

[0240] Meanwhile, in order to achieve site-specific coupling of fatty acid chains, this invention mutates some sites to Lys, and mutates the K (Lys) at the original sites to R or other hydrophilic amino acids (such as S and T), as shown in Table 3 below.

[0241] Table 3: Site-directed coupling sites of fatty acid chains in IGF-1 mutants

[0242] The IGF-1 mutants were finally obtained as shown in Table 1. The specific amino acid sequences of the protein were confirmed by structural analysis and activity analysis of all mutation sites. The mutations did not affect the original activity of IGF-1.

[0243] Example 1.2: Preparation of IGF-1 mutant

[0244] The IGF-1 mutant expression plasmid was transformed into BL21(DE3). Single clones were picked from the transformation plate and cultured. When the OD600 was 0.5, the culture was preserved and expanded. At around OD600 0.5, 0.3 mM IPTG was added and the culture was incubated overnight at 25°C to induce the expression of the target protein.

[0245] The expressed bacterial cells were collected at 8000 rpm for 20 min. Pre-cooled lysis buffer was added at a ratio of 1 gram of wet bacterial cells to 100 ml of lysis buffer (25 mM Tris-HCl, 5 mM EDTA, 150 mM NaCl, 1 mM PMSF, pH 8.5). The cells were then subjected to high-pressure lysis, and inclusion bodies were collected at 18000 rpm.

[0246] Inclusion bodies were washed 3-4 times with a washing buffer consisting of 20 mM Tris, 300 mM NaCl, 1 mM EDTA, 1% TX100, pH 8.5, for 15 minutes each time. Then, inclusion bodies were denatured at a ratio of 1 g of wet inclusion bodies to 100 ml of denaturing buffer (20 mM Tris, 8 M Urea, 0.1 mM EDTA, pH 8.5) overnight at 4°C. The denatured inclusion bodies were centrifuged at 20,000 rpm, the supernatant was collected, filtered, and the concentration was measured using the Bradford method. The mixture was then slowly added dropwise to a 20-fold dilution for refolding.

[0247] The refolding solution was processed using CHT and Superdex 75 to remove host cell protein (HCP), host cell DNA (HCD), dimers, and multimers. IGF-1 mutants with mispaired disulfide bonds were removed using a C8 column. The final IGF-1 mutant stock solution, with a purity greater than 95%, was used for fatty acid chain coupling.

[0248] Experimental results showed that the total protein expression of inclusion bodies in M59A and M59T was lower than that in the unmutated group. The expression levels of inclusion bodies in M59V, M59I, and M59L were superior to or comparable to those in the unmutated IGF-1.

[0249] The protein purity of the purified IGF-1 mutant is shown in Table 4.

[0250] Table 4: Protein expression assay of IGF-1 mutants

[0251] The effect of amino acid mutation at position 59 on disulfide bond renaturation efficiency was assessed to evaluate the renaturation efficiency, and the correct pairing rates of wild-type and mutant proteins were measured. The results showed that the correct pairing rate of the wild-type (M59) protein was 60.0%. When position 59 was mutated to valine (V) or isoleucine (I), the correct pairing rates were 52.0% and 52.0%, respectively, indicating that approximately 48% of disulfide bonds were mispaired. In contrast, after mutation to leucine (L), the correct pairing rate significantly increased to 70.0%, and the mispairing rate decreased to 30.0%. These results indicate that the L mutation is more favorable for correct disulfide bond pairing than the unmutated wild-type protein.

[0252] IGF-1 mutants P-P1370110, P-24B0320003, P-24B0320004, P-24B0320007, P-24B0320013, P-24B0320015, P-24B0320016, P-24B0320017, P-24B0320018, P-24B0320019, and P-24B0320038 were analyzed by SDS-PAGE, reversed-phase high-performance liquid chromatography (RP-HPLC), and whole molecular weight mass spectrometry (Intact MS). The results showed that each mutant exhibited a single target band by SDS-PAGE, with no obvious degradation or contaminating proteins, and the band positions were consistent with the expected molecular weights. RP-HPLC analysis indicated that the purity of the main peak of each mutant was greater than 90%, and the protein homogeneity was good. The molecular weights determined by Intact MS were highly consistent with the theoretical values, further confirming that the primary structures of each mutant were correct and the molecular weights met expectations.

[0253] Example 2: Design and preparation of IGF-1 fatty acid derivatives

[0254] Example 2.1: Design of IGF-1 fatty acid derivatives

[0255] Wild-type IGF-1 (SEQ ID NO:1) or the IGF-1 mutant described in Example 1 is coupled with fatty acid groups via linkers. The specific groups coupled are Z1, Z2, Z3 or Z4 groups as shown in Table 5 below.

[0256] Table 5-1: Meaning of Z1, Z2, Z3, and Z4

[0257] The sites on which the fatty acids are coupled via linkers include: the amino group of the ε side chain of a lysine residue or the amino group of the α side chain of a glycine residue in wild-type human IGF-1 (SEQ ID NO:1) or the IGF-1 mutant shown in Table 1.

[0258] Table 5-2 Intermediates used in the preparation of IGF-1 fatty acid derivatives

[0259] Example 2.2: Preparation of IGF-1 fatty acid derivatives

[0260] General purification methods

[0261] Preparative HPLC purification method (1): Reverse column chromatography purification was performed on an XBridge C18 (10 μm, 19 x 250 mm) column: mobile phase A: H2O (0.1% TFA); mobile phase B: CH3CN (0.1% TFA); elution gradient: 20% B to 80%, flow rate: 35 mL / min, total time: 24 min; dual wavelength detection at 254 nm and 214 nm was used.

[0262] Example 2.2.1: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370010 (SEQ ID NO:21)

[0263] Insulin-like growth factor (IGF-1) (SEQ ID NO: 2,5 mg, 0.6494 μmol) was dissolved in 100 mM Na2CO3, pH 10.5 (0.973 mL). At reaction times of 0 min, 20 min, 60 min, 80 min, 120 min, and 140 min, a dimethylformamide solution (40 mg / mL, 22.4 μL) of hexapeptide (S)-13-carboxy-1-((2,5-dioxopyrrolidone-1-yl)oxy)-1,10,15-trioxo-3,6-dioxa-9,14-diazatane-32-oic acid (0.89 mg, 1.2989 μmol) was added. The mixture was stirred continuously at room temperature for a total reaction time of 3 hours. After the reaction was completed by HPLC monitoring, the insulin-like growth factor (IGF-1) conjugate C-P1370010 (SEQ ID NO: 21, 2.87 mg, 0.324 μmol) was isolated by preparative HPLC purification method (1), and its specific structure is shown below:

[0264] LCMS(ES+)m / z:8840.3895(M).

[0265] Example 2.2.2: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320007 (SEQ ID NO:24)

[0266] Dissolve insulin-like growth factor (IGF-1) (SEQ ID NO:7, 17.95 mg, 2.3335 μmol) in 100 mM Na2CO3, pH 9.5 (4.3 mL). If necessary, adjust the pH to 9.0-9.5 by adding 1 M AcOH. Then, a dimethylformamide solution (42 mg / mL, 76.2 μL) of (S)-13-carboxy-1-((2,5-dioxopyrrolidone-1-yl)oxy)-1,10,15-trioxo-3,6-dioxa-9,14-diazatriadodecane-32-acid (3.2 mg, 4.667 μmol) was added. After stirring for 20 minutes, (S)-13-carboxy-1-((2,5-dioxopyrrolidone-1-yl)oxy)-1,10,15-trioxo-3,6-dioxa-9,14-diazatriadodecane-32-acid (3.2 mg, 4.667 μmol) was added. A dimethylformamide solution (42 mg / mL, 76.2 μL) of dialkyl-32-acid (3.2 mg, 4.667 μmol) was added, and the mixture was stirred continuously for 40 minutes. Then, a dimethylformamide solution (55 mg / mL, 29.1 μL) of (S)-13-carboxy-1-((2,5-dioxopyrrolidone-1-yl)oxy)-1,10,15-trioxo-3,6-dioxa-9,14-diazatriadodecane-32-acid (1.6 mg, 2.3335 μmol) was added, and the mixture was stirred continuously at room temperature for 30 minutes. After the reaction was completed by HPLC monitoring, the insulin-like growth factor (IGF-1) conjugate C-24B0320007 (SEQ ID NO: 24, 11.32 mg, 1.283 μmol) was isolated by preparative HPLC purification method (1), and its specific structure is shown below:

[0267] LCMS(ES+)m / z:8822.4832(M).

[0268] Example 2.2.3 Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370011 (SEQ ID NO:15)

[0269] Using a method similar to 2.2.1-2.2.2, fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370011 (SEQ ID NO:15) was prepared, and its specific structure is shown below;

[0270] LCMS(ES+)m / z:9354.67(M).

[0271] Example 2.2.4: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370009 (SEQ ID NO:16)

[0272] Using a method similar to 2.2.1-2.2.2, fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370009 (SEQ ID NO:16) was prepared, and its specific structure is shown below;

[0273] LCMS(ES+)m / z:9927.16(M).

[0274] Example 2.2.5: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370004 (SEQ ID NO:17)

[0275] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370004 (SEQ ID NO:17) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0276] LCMS(ES+)m / z:8298.07(M).

[0277] Example 2.2.6: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370002 (SEQ ID NO:18)

[0278] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370002 (SEQ ID NO:18) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0279] LCMS(ES+)m / z:8269.90(M).

[0280] Example 2.2.7: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370001 (SEQ ID NO:19)

[0281] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370001 (SEQ ID NO:19) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0282] LCMS(ES+)m / z:8415.1087(M).

[0283] Example 2.2.8: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370003 (SEQ ID NO:20)

[0284] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-P1370003 (SEQ ID NO:20) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0285] LCMS(ES+)m / z:8124.9569(M).

[0286] Example 2.2.9: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320003 (SEQ ID NO:22)

[0287] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320003 (SEQ ID NO:22) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0288] LCMS(ES+)m / z:8808.4699(M).

[0289] Example 2.2.10: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320004 (SEQ ID NO:23)

[0290] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320004 (SEQ ID NO:23) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0291] LCMS(ES+)m / z:8822.4539(M).

[0292] Example 2.2.11: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320013 (SEQ ID NO:25)

[0293] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320013 (SEQ ID NO:25) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0294] LCMS(ES+)m / z:8824.36(M+H).

[0295] Example 2.2.12: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320015 (SEQ ID NO:26)

[0296] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320015 (SEQ ID NO:26) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0297] LCMS(ES+)m / z:8877.39(M).

[0298] Example 2.2.13: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320016 (SEQ ID NO:27)

[0299] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320016 (SEQ ID NO:27) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0300] LCMS(ES+)m / z:8863.33(M).

[0301] Example 2.2.14: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320017 (SEQ ID NO:28)

[0302] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320017 (SEQ ID NO:28) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0303] LCMS(ES+)m / z:8822.25(M).

[0304] Example 2.2.15: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320018 (SEQ ID NO:29)

[0305] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320018 (SEQ ID NO:29) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0306] LCMS(ES+)m / z:8823.37(M).

[0307] Example 2.2.16: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320019 (SEQ ID NO:30)

[0308] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320019 (SEQ ID NO:30) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0309] LCMS(ES+)m / z:8865.37(M).

[0310] Example 2.2.17: Preparation of fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320038 (SEQ ID NO:31)

[0311] The fatty acid-modified insulin-like growth factor (IGF-1) conjugate C-24B0320038 (SEQ ID NO:31) was prepared using a method similar to 2.2.1-2.2.2, and its specific structure is shown below:

[0312] LCMS(ES+)m / z:8698.23(M).

[0313] Detailed structural information of the fatty acid-modified insulin-like growth factor conjugates prepared in Examples 2.2.1-2.2.17 above is shown in Table 2.

[0314] Example 3: In vitro cellular activity of molecules

[0315] Example 3.1 Cell viability detection based on AKT phosphorylation signaling

[0316] HEK293T cells (purchased from the Chinese Academy of Sciences Cell Bank, catalog number SCSP-502) with high IGF-1R expression on their cell surface were used to determine the phosphorylation of Akt, a downstream signaling molecule of the IGF-1 receptor, and the effect of albumin on the activity of fatty acid modification molecules.

[0317] HEK293T cells were resuscitated and passaged twice as usual until they reached 80% confluence. Cells were washed with DPBS, digested with TrypLE, and digestion was stopped by adding DMEM medium containing 10% FBS. Single-cell suspensions were prepared. Cells were collected by centrifugation at 300g for 5 min, resuspended in DMEM basal medium free of fetal bovine serum, counted, and the cell density was adjusted to 6 × 10^5 cells / mL. 100 μL of cell suspension per well was transferred to 96-well plates. The plates were incubated overnight at 37°C and 5% CO2. The next day, the experimental medium in the culture plate was discarded, and 100 μL of candidate molecules prepared with working concentration gradient in DMEM basal medium without fetal bovine serum was added to each well of the experimental plate. The mixture was incubated at 37°C and 5% CO2 for 20 minutes. The experimental medium was then aspirated to stop the reaction. Subsequently, AKT phosphorylation detection was performed according to the instructions of the pan-Akt (Phospho-Ser473) TR-FRET kit (Cisbio, catalog number: 64AKSPEHo).

[0318] Since fatty acids can form non-covalent bonds with human serum albumin (HSA), if it is necessary to detect the effect of albumin on molecular activity, fatty acid-free albumin powder (Sigma, catalog number: A3782-10G) should be prepared into a 200 mg / mL stock solution according to the instructions and stored. Albumin stock solution was prepared at a working concentration of 2x (500 μM) using DMEM basal medium, and candidate molecules were prepared at a working concentration gradient of 2x. The albumin solution and the candidate molecule gradient solutions were then mixed at a 1:1 volume ratio and incubated at 37°C for 30 minutes to allow for sufficient binding of fatty acids to albumin. Then, 100 μL of the incubated albumin and candidate molecule gradient mixture was added to each well of the experimental plate and incubated at 37°C and 5% CO2 for 20 minutes. The reaction was then stopped, and AKT phosphorylation detection was performed according to the instructions of the pan-Akt (Phospho-Ser473) TR-FRET kit (Cisbio, catalog number: 64AKSPEH). The luminescent signal (RLU) was measured using an Envision microplate reader. The EC50 values ​​of IGF-1 protein and its fatty acid-modified molecules were analyzed using a GraphPad Prism 10 with 4-parameter fitting.

[0319] Experimental results:

[0320] The AKT phosphorylation activation activity of exemplary IGF-1 mutants P-P1370110, P-24B0320003, P-24B0320004, P-24B0320007, P-24B0320013, P-24B0320015, P-24B0320016, P-24B0320017, P-24B0320018, P-24B0320019, P-24B0320038 (without fatty acid modification) and the control group increlex (commercially available) at the cellular level is shown in Table 6 and Figure 1 (A-B). The phosphorylation activation ability of the IGF-1 mutants was not significantly different from that of Increlex, and the activity of the IGF-1 molecule after the M59 mutation was comparable to that of P-P1370110 without the M59 mutation.

[0321] Table 6: Results of AKT phosphorylation activation activity of unmodified IGF-1 at the cellular level

[0322] The cellular-level AKT phosphorylation activation activity of fatty acid-modified molecules C-P1370001~C-P1370004, C-P1370009~C-P1370011 and the effect of albumin on their activity are shown in Figure 2 (A~F) and Table 7. The results show that the fatty acid-modified IGF-1 molecules can maintain their phosphorylation activation ability well while being significantly blocked by albumin. Among them, C-P1370010 is most significantly blocked by albumin.

[0323] Table 7: Results of AKT phosphorylation activation activity of fatty acid-modified IGF-1 at the cellular level

[0324] The results of phosphorylation activation of mutant molecules obtained to remove the post-translational modification problem of M59 oxidation are shown in Figure 3 (A-C) and Table 8 after fatty acid modification.

[0325] Figure 3A shows that the fatty acid-modified molecules C-P1370010, C-24B0320003, C-24B0320004, and C-24B0320007 containing the M59 mutation have comparable AKT phosphorylation activation activities to the fatty acid-modified molecule C-P1370010 without the M59 mutation; among them, the activity of molecule C-24B0320007 is closest to that of C-P1370010.

[0326] In addition, albumin also has a significant blocking effect on the modified molecules after the M59 mutation (see Figure 3B and Table 8).

[0327] Figure 3C shows that fatty acidation at different sites affects AKT phosphorylation activity.

[0328] Table 8: Results of AKT phosphorylation activation activity of fatty acid-modified IGF-1 after M59 mutation at the cellular level

[0329] In the table, 'NA' indicates that no data was detected; ' / ' indicates that no data was detected.

[0330] Example 3.2 Detection of proliferation activity based on MCF-7 cells

[0331] To investigate the cellular biological functions of the designed IGF-1 protein and its fatty acid modification molecules, MCF7 cells (purchased from Beina Biotechnology, catalog number BNCC100137) with high expression of IGF-1R on their cell surface were used to determine the biological functions of IGF-1 protein and its fatty acid modification molecules in promoting cell proliferation and the effect of albumin on the activity of fatty acid modification molecules.

[0332] After resuscitating MCF7 cells, passage them twice until they reach 80% confluence. Wash cells with DPBS, remove the washing solution, add TrypLE to digest the cells, and stop digestion by adding DMEM medium containing 10% FBS. Prepare a single-cell suspension. Centrifuge at 300g for 5 min to collect cells, resuspend in DMEM medium containing 0.1% fetal bovine serum, count the cells, and adjust the cell density to 1×10^5 cells / mL. Add 100 μL of cell suspension to each well of a 96-well plate. Incubate overnight at 37°C and 5% CO2. The next day, the experimental culture medium in the culture plate was discarded, and 100 μL of candidate molecules prepared with working concentration gradient in DMEM experimental medium containing 0.1% fetal bovine serum was added to each well of the experimental plate. The plate was incubated at 37°C and 5% CO2 for 72 hours. Then, 100 μL of CellTiter-Glo reagent (Promega, catalog number G7573) was added to each well of the experimental plate and incubated at room temperature for 10 minutes. The luminescence signal was measured using an Envision microplate reader.

[0333] To detect the effect of albumin on molecular activity, first prepare a 200 mg / mL stock solution of fatty acid-free albumin powder (Sigma, catalog number: A3782-10G) according to the instructions. As needed, prepare a working concentration (10 μM) of albumin stock solution and a working concentration gradient of candidate molecules using DMEM basal medium. Mix the albumin solution and the candidate molecule gradient solutions at a 1:1 volume ratio, thoroughly mix, and incubate at 37°C for 30 minutes to allow for sufficient binding of fatty acids and albumin. Add 100 μL of the incubated albumin and candidate molecule gradient mixture to each well of the experimental plate and incubate at 37°C and 5% CO2 for 72 hours. Add 100 μL of CellTiter-Glo reagent (Promega, catalog number G7573) to each well of the experimental plate and incubate at room temperature for 10 minutes. Measure the luminescence signal using an Envision microplate reader. EC50 values ​​of IGF-1 protein and its fatty acid modification molecules were analyzed using GraphPad Prism 10 with 4-parameter fitting.

[0334] As shown in Figure 4, the C-24B0320007 molecule has the function of promoting cell proliferation, and albumin has the effect of blocking the cell proliferation-promoting ability of this molecule.

[0335] Example 4: Molecular Binding Dynamics

[0336] Example 4.1 Surface plasmon resonance technique was used to determine the binding kinetics of different mutant molecules to the human IGF-1 receptor.

[0337] The effect of albumin on the affinity of the molecule of this invention for the human IGF1R receptor was determined using the Biacore 8K (Cytiva) surface plasmon resonance (SPR) biosensor. The human IGF1R receptor protein was immobilized on an SA chip, with the IGF-1 protein of this invention used as the analyte. Binding to the analyte was detected at a flow rate of 30 μL / min using an experimental buffer at 25°C and a binding time of, for example, 120 s binding and dissociation times. After each cycle of dissociation, the biochip was washed and regenerated using a 1:1 mixture of 10 mM glycine-hydrochloric acid solutions at pH 2.5 and pH 3.0. Data on the binding (ka) and dissociation (kd) rate constants were obtained using the Biacore 8K evaluation software. The equilibrium dissociation constant (KD) was determined by the ratio of kd to ka.

[0338] Table 9 shows the binding kinetics of IGF-1 protein molecules and their fatty acid derivatives to the receptor of IGF-1 in the above assay methods. The results show that there were no significant differences in affinity levels between IGF-1 proteins of different mutants and between fatty acid derivatives of IGF-1 proteins of different mutants.

[0339] Table 9: Binding kinetics of IGF-1 protein molecules and their fatty acid derivatives with IGF-1 receptors from different mutants

[0340] Example 4.2 Surface plasmon resonance technique was used to determine the binding kinetics of molecules with IGF-1 receptors of different species.

[0341] The affinity of the molecule of this invention for IGF1R receptors of different species was determined using the Biacore 8K (Cytiva) surface plasmon resonance (SPR) biosensor. His-tagged receptor proteins of different species were immobilized on the sensor chip using a His-chip capture method, with the IGF-1 protein of this invention used as the analyte. Binding to the analyte was detected at a flow rate of 30 μL / min using an experimental buffer at 25°C and a binding time of, for example, 120 s binding time and a dissociation time of 120 s. After each cycle of dissociation, the biochip was washed and regenerated with a 10 mM glycine-hydrochloric acid solution at pH 1.5. Data on the binding (ka) and dissociation (kd) rate constants were obtained using Biacore 8K evaluation software; the equilibrium dissociation constant (KD) was determined by the ratio of Kd to Ka.

[0342] The binding kinetics of C-P1370010 and C-24B0320007 to IGF-1 receptors in humans, rats, mice and cynomolgus monkeys are shown in Table 10. No significant differences were observed in affinity levels.

[0343] Table 10: Binding kinetics of IGF-1 fatty acid derivatives to IGF-1 receptor

[0344] Example 5: Pharmacodynamic study in C57 mouse model

[0345] This study used 4-week-old C57BL / 6J mice in their rapid weight gain phase, and administered a single injection of a GHR antagonist antibody (from Changchun Jinsai, denoted as Blocker) to inhibit mouse growth. The growth-promoting efficacy of the test molecule was evaluated in this growth-inhibition model. The model animals were divided into three groups: a negative control PBS group (denoted as G2 Blocker+PBS), a positive reference group Increlex group, and test molecule groups (C-P1370002, C-P1370009, C-P1370010, C-P1370011), with 8 mice in each group. The Increlex group received continuous administration via a mini-injector. After infusion, Increlex was equilibrated overnight in sterile saline at 37°C and then transplanted onto the animal's back. The PBS group and the test molecule group received subcutaneous injection. Wild-type mice were injected with phosphate-buffered saline (PBS) as a normal control group (denoted as G1 PBS+PBS). The experiment lasted 7 days, with daily monitoring of weight and blood glucose changes at fixed times.

[0346] As shown in Figure 5, the results of weight gain showed that molecules C-P1370010 and C-P1370011 had the strongest promoting effect on weight gain in mice, and there was no significant difference in their effects.

[0347] The effect of C-P1370010 on blood glucose in mice is shown in Figure 6. No significant fluctuations in blood glucose were observed in wild-type mice treated with 3 mg / kg and 10 mg / kg doses. The maximum decrease in blood glucose after treatment with 30 mg / kg dose was about 50%, and it basically recovered after 24 hours.

[0348] Example 6: Pharmacodynamic study in a GH receptor gene knockout mouse model

[0349] Example 6.1 Glucose tolerance

[0350] Methods: Eighty-four 9-10 week old male SPF-grade growth hormone receptor (GHR) knockout mice from Nanmo Biotechnology were acclimatized for more than 7 days. All animals were weighed, and 72 animals with minimal weight dispersion were selected and grouped according to weight and blood glucose levels. They were divided into nine groups: a model control group (solvent: buffer solution containing 1.34 mg / mL Na2HPO4 + 44 mg / mL Mannitol, pH 6.8), doses A-E of the test sample C-24B0320007 (dissolved in the solvent), high- and low-dose positive control drug (PC, Increlex), and a control group C-P1370010. The drug was administered via a single subcutaneous injection in the neck and back, with a volume of 10 mL / kg. Blood glucose was measured by blood collection from the tail tip of all animals before administration and at 0.25, 0.5, 1, 2, 4, 6, 8, 24, and 48 hours after administration. Specific grouping and administration information are shown in Table 11.

[0351] Table 11:

[0352] Results: No animal deaths were observed after administration. All treatment groups showed dose-dependent hypoglycemia. The maximum hypoglycemia in the PC group was approximately 40–50%, occurring 0.5–1 hour after administration; the maximum hypoglycemia in the test sample group was approximately 23–40%, occurring 1–4 hours after administration; and the maximum hypoglycemia in the C-P1370010 group was approximately 35%, occurring 6 hours after administration, with blood glucose essentially returning to normal after 24 hours. The maximum hypoglycemia in all test sample dose groups did not exceed that in the PC group. The maximum hypoglycemia in the 7.5 mg / kg and 10 mg / kg test sample dose groups was similar to that in the 0.5 mg / kg PC dose group, indicating that the test sample had better glycemic safety than PC, possibly related to the sustained release of the drug in vivo (see Figures 7A and 7B for details).

[0353] Example 6.2 Growth-promoting in vivo efficacy

[0354] Methods: One hundred and five male SPF-grade GHR knockout mice aged 9–10 weeks (weighing 10–19 g) and six wild-type mice (WT, weighing 18–22 g) were acclimatized for more than 7 days. Sixty-six GHR knockout mice with low dispersion in body weight and random blood glucose were selected and randomly divided into 11 groups based on body weight and random blood glucose: model control group, PC sustained-release group, low-dose PC group, high-dose PC group, test sample sustained-release group, and test sample A, B, C, D, E, and F dose groups, with six mice in each group. Six WT mice served as the normal control group. The sustained-release groups received medication via an implantable capsule osmotic pump (each capsule contained 100 μL of medication; the required concentration was calculated and prepared based on the average body weight of the animals in the group before administration, and the capsules were implanted). The medication was administered once daily for 14 days. Body weight was measured once daily from D0 to D14. Body length (from nose tip to anus) and tail length (from anus to tail tip) were monitored on the day following the last dose (D14). Tibial bones were also taken from both sides to measure tibial length and epiphyseal plate thickness. Specific grouping and dosage information are shown in Table 12 below.

[0355] Table 12: Grouping and Dosage Information

[0356] (QD: once daily; BID: twice daily; 14D: continuous administration for 14 days; Q2D: once every two days; solvent is a buffer solution containing 1.34 mg / mL Na2HPO4 + 44 mg / mL Mannitol, pH 6.8.)

[0357] Results: In the high-dose PC group (1.5 mg / kg BID), one animal died on days 5 and 12 respectively; in the test sample group (5 mg / kg QD), one animal died on day 5, and in the 7.5 mg / kg QD group, one animal died on day 9. No other deaths were observed.

[0358] Compared to the model control group, all drug-treated groups showed significantly faster weight gain after administration, and all groups experienced faster weight gain than WT mice. The high and low dose subcutaneous PC group showed similar weight gain rates to WT mice, while the sustained-release group showed faster weight gain than WT mice. In the test sample group, dose-related factors promoted faster weight gain. After 14 days of administration, compared to the high and low dose subcutaneous PC group, the sustained-release group and all QD dose groups showed significantly increased or increasing weight changes, with the Q2D group showing an increasing trend. Compared to the PC sustained-release group, the sustained-release group and the 5 mg / kg QD and 7.5 mg / kg QD groups showed similar or increasing weight changes. See Figure 8A for details.

[0359] The trends in body length and tail length are similar to those in weight, as detailed in Appendix 8B.

[0360] The results for tibial length and epiphyseal plate thickness were similar. Compared with the model control group, tibial length and epiphyseal plate thickness were significantly increased or trending upward in all treatment groups. The QD dose-related increase in tibial length and epiphyseal plate thickness was observed in the test sample groups; tibial length and epiphyseal plate thickness with 3 and 5 mg / kg Q2D administration were similar to those with 1.5 mg / kg QD administration. Tibial length and epiphyseal plate thickness in the test sample groups were similar to or better than those with subcutaneous PC administration. The extended-release test product group and the 3, 5, and 7.5 mg / kg QD administration groups were similar to or better than the extended-release PC group (see Figures 8C and 8D for details).

[0361] Considering the glycemic safety and growth-promoting pharmacological effects of the test sample in GHR gene mutant mice, the test sample has the potential to reduce the dosing frequency and the risk of hypoglycemia while maintaining or even surpassing the efficacy of PC.

[0362] Example 7: Pharmacodynamic study in a pituitary-deprived rat model

[0363] Example 7.1 Glucose Tolerance

[0364] Methods: Healthy SPF-grade male SD rats were selected to construct a pituitary deprivation rat model. After anesthetizing the rats with 25% urethane via intraperitoneal injection, a hole was drilled at the sphenopalatine symphysis to remove the pituitary gland, and the wound was sutured. The rat weight before administration was monitored; a difference of less than 10% from the first postoperative weight was considered a successful model. Twenty-one successfully modeled animals were selected and divided into seven groups: a solvent control group, test sample (C-24B0320007) doses A-E, a positive control drug (PC, Increlex) group, and a single subcutaneous injection in the neck and back. Blood glucose levels were measured before administration and at pre, 0.5h, 1h, 4h, 8h, 24h, 48h, and 72h after administration. Specific grouping and dosage information are shown in Table 13 below.

[0365] Table 13:

[0366] Results: In the 9 mg / kg and 13.5 mg / kg dose groups of the test samples, one and two animals died 24 hours after administration, respectively, indicating that excessive dosage may lead to glycemic intolerance. The dose-dependent reduction in blood glucose was observed in the test sample groups. The maximum reductions in dose groups A through E were 6.2%, 21.4%, 41.6%, 69.2%, and 63.7%, respectively, occurring 4–8 hours after administration and essentially recovering by 24 hours. In the PC group (0.25 mg / kg subcutaneous administration), the maximum reduction in blood glucose was approximately 43.2%, occurring 0.5–1 hour after administration and essentially recovering by 4 hours. The maximum reduction in blood glucose in the 6 mg / kg test sample group was similar to that in the 0.25 mg / kg PC group (see Figure 9A for details).

[0367] Example 7.2 Growth-promoting effects

[0368] Methods: A pituitary deprivation rat model was constructed using healthy SPF-grade male SD rats. Sixty-four successfully modeled rats were divided into eight groups: a solvent control group (containing 1.34 mg / mL Na₂HPO₄ + 44 mg / mL Mannitol, pH 6.8 buffer), a PC sustained-release group, a PC subcutaneous group, a test sample sustained-release group, a test sample QD 1–3 dose subcutaneous administration group, and a test sample Q2D subcutaneous administration group. The drugs were administered via subcutaneous injection into the neck and back for a total of four weeks. Weight was recorded daily during the administration period. Body length and tail length were measured before and at the end of the experiment. Tibial length was measured at the end of the experiment, and epiphyseal plate thickness was also measured. Specific grouping and dosage information are shown in Table 14 below.

[0369] Table 14

[0370] Results: See Figure 9B for the trend of body weight change; Figure 9C for the epiphyseal plate thickness; and Figure 9D for the tibial length. The trends of body weight, tibial length, and epiphyseal plate thickness were similar. All treatment groups showed significantly higher growth-promoting effects compared to the solvent control group. The test sample groups showed a dose-response relationship in growth-promoting indicators such as accelerated body weight gain and bone growth. Furthermore, the efficacy of 4 mg / kg Q2D and 2 mg / kg QD in the test sample groups was similar, and the efficacy of 4 and 6 mg / kg QD in the test sample groups was similar to that of the PC group (minipump), indicating a potential for reducing dosing frequency.

[0371] Example 8: Pharmacokinetic Study of IGF-1 Fatty Acid Derivatives

[0372] Example 8.1 Single-dose pharmacokinetic assay in C-P1370010 mice

[0373] This experiment was used to test the PK of C-P1370010 in the serum of mice.

[0374] Animal preparation: Twelve male C57BL / 6J mice were used. Animals were weighed and their weight recorded before administration. All animals had free access to food and water before administration. A single subcutaneous injection of 8 mg / kg was administered. Blood samples were collected at different time points after administration (before administration (0h), and 0.5h, 1h, 2h, 4h, 8h, 24h, 48h, 72h, 120h, and 168h after administration). Six animals were collected at each time point, and blood samples were collected alternately according to the experimental design.

[0375] Sample analysis: The content of C-P1370010 in serum was detected. LC-MS / MS was used for detection. Sample pretreatment involved protein precipitation, followed by analysis using an AB Sciex QTRAP6500+ instrument.

[0376] PK parameter analysis: A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Analyzed blood drug concentration-time data.

[0377] PK parameters include (if data allows) but are not limited to peak concentration (C0). max Peak time (T) max Eliminate half-life (T) 1 / 2 The parameters include the area under the serum concentration-time curve (AUC), mean residence time (MRT), etc. The meanings and calculation formulas for each PK parameter are shown in Table 15 below.

[0378] Table 15: Pharmacokinetic Parameters

[0379] Example 8.2 C-P1370010 rat single-dose pharmacokinetic assay

[0380] This experiment was used to test the PK of C-P1370010 molecules in rat serum.

[0381] Animal preparation: Twelve male Sprague Dawley (SD) rats were used, with four rats per group. Animals were weighed and their weight recorded before administration. All animals had free access to food and water before administration. Single subcutaneous injections were administered at doses of 4.04 mg / kg, 8.08 mg / kg, and 16.16 mg / kg. Blood samples were collected at different time points after administration (before administration (0h), and 2h, 4h, 8h, 24h, 48h, 72h, 96h, 120h, 144h, and 168h after administration). Four animals were collected at each time point.

[0382] Sample analysis: The content of C-P1370010 in serum was detected. LC-MS / MS was used for detection. Sample pretreatment involved protein precipitation, followed by analysis using an AB Sciex QTRAP6500+ instrument.

[0383] PK parameter analysis: A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Analyzed blood drug concentration-time data.

[0384] The PK parameters and calculation formulas are the same as in section 8.1.

[0385] Example 8.3 C-P1370010 Single-dose PK test in dogs

[0386] This experiment was used to test the PK of the C-P1370010 molecule in serum in dogs.

[0387] Animal preparation: Three male beagle dogs were used. Their weight was recorded before administration. All animals had free access to food and water before administration. A single subcutaneous injection of 0.5 mg / kg was administered. Blood samples were collected at different time points after administration (before administration (0h), and 0.5h, 1h, 2h, 4h, 6h, 8h, 24h, 32h, 48h, 56h, 72h, 96h, 120h, 144h, 168h, 216h, 264h, and 336h after administration). Three animals were collected at each time point.

[0388] Sample analysis: The content of C-P1370010 in serum was detected. LC-MS / MS was used for detection. Sample pretreatment involved protein precipitation, followed by analysis using an AB Sciex QTRAP6500+ instrument.

[0389] PK parameter analysis: A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Analyzed blood drug concentration-time data.

[0390] The PK parameters and calculation formulas are the same as in section 8.1.

[0391] The PK results of C-P1370010 in the serum of mice, rats and beagle dogs are detailed in Figures 10 to 12 and Table 17.

[0392] Table 16: PK Results of C-P1370010

[0393] Example 8.4: Subcutaneous drug administration and pharmacokinetic assay in GHR gene knockout mice (C-24B0320007GHR gene knockout mice)

[0394] This experiment was used to test the PK of the C-24B0320007 molecule in mouse serum.

[0395] Animal preparation: Eighteen male growth hormone receptor (GHR) knockout mice were used, with six mice in each group. Animals were weighed and their weight recorded before administration. All animals had free access to food and water before administration. Single and multiple subcutaneous injections were administered. The single dose was 3 mg / kg and 7.5 mg / kg, and the multiple dose was 7.5 mg / kg, administered once daily for 7 consecutive days. Blood samples were collected at different time points after single subcutaneous injection (before administration (0h), and 1h, 4h, 8h, 24h, 48h, and 72h after administration). Blood samples were collected at the following time points after multiple administrations: 0h before administration on D0, and 1h, 4h, 8h, and 24h after administration; before administration on D2 and D4; and before administration on D6, and 1h, 4h, 8h, 24h, 48h, and 72h after administration. Three animals were collected at each time point, with blood samples collected alternately according to the experimental design.

[0396] Sample analysis: The content of C-24B0320007 in serum was detected. LC-MS / MS was used for detection. Sample pretreatment involved protein precipitation, followed by analysis using an AB Sciex QTRAP6500+ instrument.

[0397] PK parameter analysis: A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Analyzed blood drug concentration-time data.

[0398] The PK parameters and calculation formulas are the same as in section 8.1.

[0399] Example 8.5C-24B0320007 Subcutaneous Drug Administration PK Detection in Pituitary Deprived Rats

[0400] This experiment was used to test the pharmacokinetic (PK) of the C-24B0320007 molecule in serum of pituitary-deprived rats.

[0401] Animal preparation: Twenty male hypopituitarized (HPO) rats were used, with ten rats per group. Animals were weighed and their weight recorded before administration. All animals had free access to food and water before administration. Single subcutaneous injection of 4 mg / kg and multiple subcutaneous injections of 2 mg / kg were administered Q2D. Blood samples were collected at 0h before administration, and 0.5h, 2h, 4h, 8h, 24h, 48h, 72h, 96h, 120h, and 168h after administration. For multiple administrations, blood samples were collected at 0.5h, 2h, 4h, 8h, 24h, and 48h after the first and last administrations. Five animals were collected at each time point, with blood samples collected alternately according to the experimental design.

[0402] Sample analysis: The content of C-24B0320007 in serum was detected. LC-MS / MS was used for detection. Sample pretreatment involved protein precipitation, followed by analysis using an AB Sciex QTRAP6500+ instrument.

[0403] PK parameter analysis: A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Analyzed blood drug concentration-time data.

[0404] The PK parameters and calculation formulas are the same as in section 8.1.

[0405] Example 8.6 C-24B0320007 and Incellex single-dose pharmacokinetic assay in dogs

[0406] This experiment was used to test the pharmacokinetic (PK) of C-24B0320007 and Incellex molecules (commercially available) in serum in beagle dogs.

[0407] Animal preparation: Six male beagle dogs were used and divided into two groups of three. Animals were weighed and their weight recorded before administration. All animals had free access to food and water before administration. A single subcutaneous injection was administered, with C-24B0320007 and Increlex given at doses of 0.5 mg / kg and 0.5 mg / kg, respectively. Blood samples were collected from the C-24B0320007 group at different time points after drug administration (before administration (0h), and 0.5h, 1h, 2h, 4h, 6h, 8h, 24h, 32h, 48h, 56h, 72h, 96h, 120h, 144h, 168h, 216h, 264h, and 336h after administration); blood samples were collected from the Incelex group at different time points after drug administration (before administration (0h), and 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 32h, 48h, 56h, and 72h after administration). Three animals were collected at each time point.

[0408] Sample analysis: The levels of C-24B0320007 and Increlex in serum were detected separately. LC-MS / MS was used for detection, with protein precipitation as the sample pretreatment method, followed by analysis using an AB Sciex QTRAP6500+ instrument.

[0409] PK parameter analysis: A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Analyzed blood drug concentration-time data.

[0410] The PK parameters and calculation formulas are the same as in section 8.1.

[0411] The PK results of serum C-24B0320007 in GHR gene knockout mice, pituitary deprivation rats and beagle dogs are shown in Figures 13A, 13B, 13C and Tables 17-18.

[0412] Table 17: PK results of C-24B0320007 in mice and rats

[0413] Table 18. Comparison results of C-24B0320007 and Incellex in Beagles

[0414] Example 9: Assessment of the effects of H2O2 oxidative stress on cell damage

[0415] This embodiment evaluates SH-SH5Y cell viability through three steps: cell culture, establishment of an H2O2 oxidative stress model, and determination of cell viability using the MTT assay. The methods are as follows:

[0416] Using the SH-SY5Y cell line (purchased from ATCC), when the SH-SY5Y cells reached 80% confluence in culture dishes, 50,000 cells were seeded into 96-well cell culture plates, designated as Day 0. After 24 hours of culture (Day 1), the stock solution of the fatty acid-modified IGF-1 conjugate C-24B0320007 was serially diluted with solvent (1.34 mg / mL Na2HPO4 + 44 mg / mL Mannito, pH 6.8) to 10, 25, 50, 100, 200, 300, and 400 μM (1000x final concentration), and then further diluted with DMEM / F12 + 1% PS basal medium (without FBS) to final concentrations of 10, 25, 50, 100, 200, 300, and 400 nM (1x). Discard the original culture medium, then add 200 μL of a solution containing the 1x compound to each well according to the plate map, and incubate for 24 h. At 24 h (Day 2), add 2 μL of 5 mM H₂O₂ to each well according to the plate map, and incubate for another 24 h (Day 3) to assess cell viability. [The following sentence appears to be incomplete and possibly refers to a separate, unrelated instruction: "Prepare in advance..."] The chemiluminescence cell viability assay kit (purchased from Promega, catalog number: [product number missing]) was thawed and warmed to room temperature. After warming, CellTiter- [missing information] was used to [missing information]. Buffer poured in Dissolve the culture medium in the substrate and set aside. Remove the 96-well plate from the incubator, discard 100 μL of culture medium from each well, and add 100 μL of the prepared CTG reagent to each well at a 1:1 ratio. Incubate on a shaker at room temperature for 10 min. Then, use a multimode plate reader to record the luminescence signal intensity to obtain the RLU. Cell viability % = (experimental group RLU - Blank RLU) / (control group RLU - Blank RLU). A positive control group was set up: cells were treated with 50 μM H2O2 + 10 nM IGF-1; experimental groups were treated with 50 μM H2O2 + different concentrations (0–400 nM) of fatty acid-modified IGF-1 conjugate C-24B0320007; a negative control group was set up: cells without any treatment.

[0417] The results are shown in Figure 14. The figure shows that the cell viability of the positive control group was twice that of the negative control group, indicating that the cell survival rate significantly improved after the addition of IGF-1, confirming that IGF-1 can effectively alleviate H2O2-induced SH-SY5Y cell damage. In the experimental groups, after H2O2 treatment, the cell survival rate decreased by 50% in the group with a C-24B0320007 concentration of 0. However, as the concentration of C-24B0320007 increased, within the range of 10–300 nM, C-24B0320007 dose-dependently increased the survival rate of H2O2-treated cells, suggesting a protective effect against oxidative stress damage. The cell viability of the 100–400 nM concentration group was significantly higher than that of the negative control group, and the protective effect was more significant in the 200–400 nM concentration group (P < 0.01).

[0418] Example 10: Evaluation of protective effect against focal cerebral ischemia-reperfusion injury in rats

[0419] A rat model of transient middle cerebral artery occlusion (tMCAO) leading to cerebral ischemia-reperfusion injury can be established. After TTC staining, normal brain tissue appears red, while the infarcted area appears white. This example uses the suture occlusion method to establish a rat model of cerebral ischemia-reperfusion injury induced by transient middle cerebral artery occlusion (tMCAO). The method is as follows:

[0420] Male SD rats weighing 230-260g were purchased and anesthetized with sulfadiazine and thiamethoxam (purchased from Jiangsu Kunchen Biotechnology Co., Ltd.). A midline incision was made in the neck to expose and free the common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA). A suture was threaded through one carotid artery for later use. A slipknot was tied at the proximal end of the common carotid artery (CCA) to temporarily block blood supply. The proximal end of the external carotid artery was ligated, and the internal carotid artery was clamped with an arterial clamp. A double knot was tied in the external carotid artery (ECA), and the external carotid artery (ECA) was severed between the double knots. The external carotid artery was straightened to be in a straight line with the common carotid artery. A small incision was made below the ligation site of the external carotid artery using microscissors, and a suture plug was inserted through the small incision. The direction of the suture plug was adjusted to enter the internal carotid artery (ICA) until it reached the intersection of the middle cerebral artery and the circle of Willis. After 85 minutes of ischemia, the rats were injected intravenously. Five minutes after administration, under isoflurane anesthesia, the neck incision was opened, the suture plug was removed, and reperfusion was performed. Then, the external carotid artery was ligated, and the neck incision was sutured. Animals were sacrificed 24 hours after reperfusion, and brains were harvested. Six coronal sections were prepared from each brain, stained with TTC, and the volume of normal tissue on the infarcted side and the volume of brain tissue on the contralateral side were analyzed using ImageJ software to calculate the cerebral infarction rate (percentage). A blank control group was established, injected with solvent (1.34 mg / mL Na2HPO4 + 44 mg / mL Mannitol, pH 6.8); the experimental group was injected with fatty acid-modified IGF-1 conjugate C-24B0320007 (9, 12, and 25 mg / kg, mg / kg abbreviated as mpk); and the drug control group was injected with edaravone dexborneol (commercially available styrax injection, 3.75 mg / kg).

[0421] The results are shown in Figure 15, which illustrates the percentage data of cerebral infarction rate (infarct volume) in the blank control group (vehicle group) and the experimental groups at different concentrations. Compared with the blank control group with added solvent, all three concentrations of experimental groups showed a reduction in cerebral infarction rate. The addition of 12 and 25 mg / kg of C-24B0320007 significantly reduced the cerebral infarction rate. This data indicates that C-24B0320007 significantly improved ischemia-reperfusion injury in the rat tMCAO model and has a protective effect against rat cerebral ischemia-reperfusion injury. Drug control group: In the rat tMCAO model, the effect of simvastatin on reducing cerebral infarction rate was not significantly different from the blank control group, and no obvious neuroprotective effect was observed. This result is presumably because the neuroprotective mechanism of simvastatin is anti-inflammatory and free radical scavenging, with a short half-life. Clinically, it is required to be administered within 48 hours of onset, twice daily via intravenous infusion. In this experiment, the drug was administered before perfusion, hence the lack of effect. In contrast, different doses of C-24B0320007 administered before reperfusion in the tMCAO model showed a dose-related significant improvement in ischemia-reperfusion injury, suggesting that its mechanism of action may not depend on a specific timing of administration or have a broader protective window.

[0422] Example 11: Evaluation of pharmacokinetic properties in rats

[0423] In vivo brain distribution studies were conducted on the fatty acid-modified IGF-1 conjugate C-24B0320007. The permeability of the molecular blood-brain barrier (BBB) ​​was evaluated in normal rats (part 11.1) and rats with a cerebral infarction model (part 11.2). The results showed that in the cerebral infarction model rats, administration of C-24B0320007 resulted in high exposure on the infarcted side, while exposure was relatively low on the contralateral non-infarcted side and in normal rats. This indicates that the fatty acid-modified IGF-1 conjugate of this invention can cross the BBB and exert its corresponding pharmacological effects even in conditions of blood-brain barrier impairment (e.g., ischemic stroke).

[0424] Example 11.1 Pharmacokinetic Study of C-24B0320007 in Plasma, Cerebrospinal Fluid, and Brain Tissue of SD Rats

[0425] Thirty-six male SD rats (n=12 per group) were used. Animals were weighed and their weight recorded before administration. All animals had free access to food and water before administration. A single tail vein injection was administered at doses of 6 mg / kg, 12 mg / kg, and 25 mg / kg. Plasma, cerebrospinal fluid, and brain tissue samples were collected at time points: before administration (0 h), and at 0.5 h, 2 h, and 24 h after administration (the brain was thoroughly perfused before collection). Three animals were collected at each time point. Drug concentrations in plasma, cerebrospinal fluid, and brain tissue were determined using LC-MS / MS. A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Calculate pharmacokinetic parameters, such as AUC. last C max T max The results are shown in Table 19. The numerical values ​​show that, in normal animals with an intact blood-brain barrier, the exposure level of the fatty acid-modified IGF-1 conjugate C-24B0320007 to brain tissue (C...) max and AUC last () is relatively low.

[0426] Table 19 Results of pharmacokinetic studies of plasma, cerebrospinal fluid, and brain tissue in SD rats.

[0427] Example 11.2 Pharmacokinetic Study of C-24B0320007 in Plasma, Cerebrospinal Fluid, and Brain Tissue in a Rats with a Temporary Middle Cerebral Artery Occlusion-Reperfusion (tMCAO) Model

[0428] A focal cerebral ischemia model was established in rats by unilateral occlusion of the middle cerebral artery using the suture embolization method (same as in Example 10). Forty-five rats with the tMCAO model were used, with 15 rats per group. Animals were weighed and their weight recorded before drug administration. All animals had free access to food and water before administration. After 1.5 hours of ischemia, the suture was removed and reperfusion was performed. A single tail vein injection was administered 5 minutes before reperfusion. The experimental groups injected with C-24B0320007 were given doses of 6 mg / kg, 12 mg / kg, and 25 mg / kg. Plasma, cerebrospinal fluid, and brain tissue (infarcted and non-infarcted areas) were collected before administration (0 h) and at 0.5 h, 2 h, 6 h, 24 h, and 48 h after administration. The brain was thoroughly perfused before collection. Three animals were collected from each group at each time point. Drug concentrations in plasma, cerebrospinal fluid, and brain tissue were detected using LC-MS / MS. A non-compartmental model was used. (Version 8.3.3.33, Pharsight, Mountain View, CA) Calculate pharmacokinetic parameters, such as AUC. last C max T max The results are shown in Table 20. The exposure level of the fatty acid-modified IGF-1 conjugate C-24B0320007 on the infarct side in model animals (C...) max and AUC last The exposure level was relatively high, and the exposure level generally increased with dose. The exposure level on the contralateral non-infarction side (C) was relatively high. max and AUC last The relatively low level of the fatty acid-modified IGF-1 conjugate C-24B0320007 indicates that the molecule can enter the brain via the BBB in the state of blood-brain barrier impairment (e.g., ischemic stroke) and accumulate on the damaged side of the brain to exert the corresponding drug effect.

[0429] Table 20 Pharmacokinetic results of plasma, cerebrospinal fluid and brain tissue in tMCAO model rats

[0430] Example 12: Study on the proliferative capacity and angiogenesis promotion ability of vascular endothelial cells

[0431] To characterize the ability of the fatty acid-modified IGF-1 conjugate of the present invention to promote vascular endothelial cell proliferation and angiogenesis, its angiogenesis ability was determined using HUVEC cells (purchased from BLUEFBIO Life Sciences, catalog number: BFN607200285) through the following steps.

[0432] Example 12.1 Experiment on the proliferation capacity of vascular endothelial cells:

[0433] Cell pretreatment: HUVEC cells were revived and passaged twice in human vascular endothelial cell culture medium (Gibco, M200PRF500) containing 2% serum as a growth supplement (purchased from Gibco, catalog number: S-003-10). Once the cells reached 80% confluence, experiments could be performed. The cells were then starved for 16 hours the day before the experiment using human vascular endothelial cell basal medium.

[0434] On the day of the experiment, the cells were digested, centrifuged, washed and resuspended, and then resuspended in human vascular endothelial cell basal medium containing 0.1% serum instead of growth additives. The cell density was adjusted to 1×10^5 cells / mL, and 50 μL of cell suspension was added to each well of a 96-well plate (i.e., 5000 cells were seeded per well).

[0435] Experimental group setup: Experimental group C-24B0320007 was serially diluted 2.5-fold starting from 1500 nM, with a blank control group of 0% concentration added simultaneously. After mixing, the cells were allowed to settle and then incubated in a cell culture incubator at 37°C and 5% CO2 for 96 hours. After incubation, 100 μL of CellTiter-Glo assay reagent (Promega, catalog number G7573) was added to each well of the experimental plate and incubated at room temperature for 10 minutes. The luminescence signal was measured and the EC50 value was calculated using an Envision microplate reader.

[0436] The results are shown in Table 21: As can be seen from the EC50 values, compared with the blank control group, the C24B0320007 molecule of this invention has the function of promoting the proliferation of human vascular endothelial cells in vitro.

[0437] Table 21 EC50 Values

[0438] Example 12.2 Experimental study on the ability to promote angiogenesis:

[0439] The day before the experiment, Geltrex was used. TM The LDEV-free, low-growth factor basement membrane matrix (purchased from Gibco, catalog number: A1413202) was transferred from a -20°C freezer to a 4°C freezer and thoroughly dissolved to ensure complete melting. On the day of the experiment, 50 μL of matrix gel was added to each well of a 96-well plate for coating under ice bath conditions. After coating, the 96-well plate was placed in a 37°C, 5% CO2 cell culture incubator for 30 minutes to allow the matrix gel to solidify into a uniform surface for use in cell culture experiments.

[0440] Pretreated cells (using the same method as in section 12.1) were digested, centrifuged, and collected. The cells were resuspended in human vascular endothelial cell basal medium, and the cell density was adjusted to 8 × 10⁵ cells / mL for subsequent plate formation. 50 μL of the test drug solution was added to each well of the matrix gel-coated experimental plate, along with 50 μL of a cell suspension at a density of 8 × 10⁵ cells / mL. Experimental groups C-24B0320007 were prepared at concentrations of 1000, 100, 1, and 0 nM, forming an incubation system with a cell density of 40,000 cells / well. The experimental plates were incubated at 37°C and 5% CO₂ for 16 hours. After incubation, high-content cell imaging was performed using a PerkinElmer or Opera Phenix Plus instrument to record the results in tubes. The results are shown in Figures 16-17, which show that the ability of C-24B0320007 to promote tube formation in human vascular endothelial cells increases with increasing concentration.

[0441] Based on the above in vitro experiments, it can be inferred that the fatty acid-modified IGF-1 conjugate of the present invention is effective in improving tissue ischemia or treating diseases related to angiogenesis disorders.

[0442] Example 13: Efficacy study of C-24B0320007 on hyperoxia-induced bronchial hypoplasia in newborn rats

[0443] This study investigated the therapeutic effect of C-24B0320007 on hyperoxia-induced bronchial hypoplasia in newborn rats and evaluated its efficacy.

[0444] C-24B0320007 molecules were prepared into different concentrations using solvents (5.68 mg / mL Na2HPO4, 14 mg / mL PG, pH 8.01) to achieve dosages of 0.12 mg / kg, 0.4 mg / kg, and 1.2 mg / kg. A solvent group (vehicle group) was also prepared simultaneously.

[0445] Preparation of a hyperoxia-induced neonatal rat bronchogenic hypoplasia model: Pregnant SD rats at 14-16 days of gestation (purchased from Zhejiang Vital River Laboratory Animal Technology Co., Ltd.) were acclimatized to a normoxic environment (two female rats per cage were used for alternating hyperoxia and normoxic lactation). After giving birth, the offspring of one pregnant rat were placed in the normoxic group (Normal group, air oxygen concentration of 21%), while the mother rat served as a backup lactating surrogate and was placed in a normoxic environment. The other female rat was then separated and, after giving birth, her offspring were placed in the hyperoxia group. On the day of birth, both the mother rat and the offspring were placed in an 85% oxygen chamber for 22 days to establish the model. To reduce the harm of hyperoxia to the lactating surrogate, the backup lactating surrogate and the parental surrogate of the offspring modeling were switched at the start and end of each day, alternating to nurse each other's offspring. The day of model establishment (i.e., when the newborn mice were discovered) was designated P1. The model group was housed in a high-oxygen environment for 22 days. Sodium lime was placed in the glass box to absorb CO2, and color-changing silica gel was placed to absorb water vapor, maintaining a humidity of 60%-70%. During the experiment, the weight of the pups was recorded every other day, and the mice were intraperitoneally injected daily with either the solvent or C-24B0320007 solution. Twenty-four hours after the last administration, the newborn mice were euthanized. Left lung tissue was collected for angiography, and the right middle lobe was collected, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned for H&E and CD31 immunohistochemical staining. H&E staining was used to observe pathological changes in the lung tissue, and radial alveolar count (RAC), mean alveolar number (MAN), and mean alveolar lining septum (MLI) were calculated. Immunohistochemistry was used to observe CD31 expression in the lung tissue and to calculate microvessel density (MVD).

[0446] Counting rules: 1. A single endothelial cell or cell cluster (not connected to other blood vessels) is counted as one microvessel. 2. Exclude vessels with a lumen diameter > 50 μm (usually mature vessels, not newly formed microvessels). 3. Avoid non-specific staining (such as alveolar macrophages).

[0447] Calculation formula: MVD = Total number of positive microvessels / Area of ​​the counting field (mm²) 2 ).

[0448] The HE staining results shown in Figures 18-20 indicate that, compared with the hyperoxia-induced model group, administration of C-24B0320007 significantly increased the number of radial alveoli and the average number of alveoli, and decreased the average alveolar liner septa, demonstrating a dose-response relationship within the range of 0.12-1.2 mg / kg. Figure 21 shows that, relative to the solvent group (vehicle group), administration of 0.12-1.2 mg / kg of C-24B0320007 significantly increased the microvascular density in the lung tissue of newborn rat pups.

[0449] The above results indicate that the fatty acid-modified IGF-1 conjugate C-24B0320007 can improve bronchial dysplasia in newborn rats.

Claims

1. An insulin-like growth factor 1 (IGF-1) fatty acid derivative or a pharmaceutical salt thereof, comprising an insulin-like growth factor 1 (IGF-1) mutant and a fatty acid; wherein the fatty acid is directly or via a linker linked to the insulin-like growth factor 1 (IGF-1) mutant.

2. The insulin-like growth factor 1 (IGF-1) fatty acidylated derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein, Compared with the amino acid sequence SEQ ID NO:1 of wild-type human IGF-1, the insulin-like growth factor 1 (IGF-1) mutant contains amino acid substitution mutations at one or more of the following positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9): position 59, position 65, position 68, position 20, position 27, position 29, position 50, position 55, and position 64; Preferably, the insulin-like growth factor 1 (IGF-1) mutant comprises an amino acid substitution mutation selected from one or more positions (i) to (ix) (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9): (i) The methionine at position 59 is substituted and mutated to any of the following amino acids: alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), leucine (M59L). (ii) The aspartic acid at position 20 is mutated and replaced with lysine (D20K); (iii) The lysine at position 27 is mutated to arginine (K27R); (iv) The threonine at position 29 was mutated to lysine (T29K); (v) The arginine at position 50 was mutated to lysine (R50K); (vi) The arginine at position 55 is mutated and replaced with lysine (R55K); (vii) The leucine at position 64 is mutated and replaced with lysine (L64K); (viii) The lysine at position 65 is mutated to arginine (K65R) or serine (K65S); (ix) The lysine at position 68 is mutated and replaced with arginine (K68R) or threonine (K68T); The mutated amino acid sites are the natural sequence sites relative to the amino acid sequence shown in SEQ ID NO:

1.

3. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein, Compared with the amino acid sequence shown in SEQ ID NO:1, the insulin-like growth factor 1 (IGF-1) mutant is selected from any of the following: (1) The insulin-like growth factor 1 (IGF-1) mutant contains amino acid substitution mutations at the following two positions: position 65 and position 68; Preferably, the insulin-like growth factor 1 (IGF-1) mutant contains amino acid substitution mutations at the following two positions: K65R and K68R; (2) The insulin-like growth factor 1 (IGF-1) mutant contains three amino acid substitution mutations selected from the following positions: position 27, position 59, position 65, and position 68; Preferably, the insulin-like growth factor 1 (IGF-1) mutant comprises three amino acid substitution mutations selected from the following positions: K27R, M59A or M59T or M59V or M59I or M59L, K65R or K65S, K68R or K68T; (3) the insulin-like growth factor 1 (IGF-1) mutant comprises five amino acid substitution mutations selected from the following positions: position 20, position 27, position 29, position 50, position 55, position 59, position 64, position 65, and / or position 68; Preferably, the insulin-like growth factor 1 (IGF-1) mutant comprises five amino acid substitution mutations selected from the following positions: D20K, K27R, T29K, R50K, R55K, M59L, L64K, K65R, K68R; Wherein, the amino acid positions of each mutation are in the natural order of the amino acid sequence set forth in SEQ ID NO:

1.

4. The insulin-like growth factor 1 (IGF-1) fatty acidylated derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein, Compared with the amino acid sequence of wild-type human IGF-1, SEQ ID NO: 1, the insulin-like growth factor 1 (IGF-1) mutant comprises: (1) at least an amino acid substitution mutation at position 59; preferably, the methionine at position 59 is substituted to alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), or leucine (M59L); and (2) the insulin-like growth factor 1 (IGF-1) mutant further comprises one or more (e.g., 1, 2, 3, or 4) amino acid substitution mutations selected from the following positions: position 65, position 68, position 20, position 27, position 29, position 50, position 55, position 64; Preferably, the insulin-like growth factor 1 (IGF-1) mutant further comprises one or more (e.g., 1, 2, 3, or 4) amino acid substitution mutations selected from the following positions: D20K, K27R, T29K, R50K, R55K, L64K, K65R or K65S, K68R or K68T; Wherein, the amino acid positions of each mutation are in the natural order of the amino acid sequence set forth in SEQ ID NO:

1.

5. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein, Compared with the amino acid sequence of wild-type human IGF-1, SEQ ID NO: 1, the insulin-like growth factor 1 (IGF-1) mutant comprises: (1) at least an amino acid substitution mutation at position 59; preferably, the methionine at position 59 is substituted to alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), or leucine (M59L); and (2) the insulin-like growth factor 1 (IGF-1) mutant further comprises any one of the following: (i) the insulin-like growth factor 1 (IGF-1) mutant further comprises an amino acid substitution mutation selected from two positions: position 27, position 65, position 68; preferably, the mutant further comprises an amino acid substitution mutation selected from two positions: K27R, K65R or K65S, K68R or K68T; (ii) the insulin-like growth factor 1 (IGF-1) mutant further comprises four amino acid substitution mutations selected from the following positions: position 20, position 27, position 29, position 50, position 55, position 64, position 65, and / or position 68; preferably, the insulin-like growth factor 1 (IGF-1) mutant further comprises four amino acid substitution mutations selected from the following positions: D20K, K27R, T29K, R50K, R55K, L64K, K65R, K68R; wherein each mutated amino acid position is relative to the natural order of amino acid sequence set forth in SEQ ID NO:

1.

6. The insulin-like growth factor 1 (IGF-1) fatty acidylated derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein, The insulin-like growth factor 1 (IGF-1) mutant comprises, compared to the amino acid sequence of wild-type human IGF-1, SEQ ID NO: 1: (1) at least an amino acid substitution mutation at position 59; preferably, the methionine at position 59 is substituted to alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), leucine (M59L); (2) at least an amino acid substitution mutation at position 65; preferably, the lysine at position 65 is substituted to arginine (K65R), or serine (K65S); (3) at least an amino acid substitution mutation at position 68; preferably, the lysine at position 68 is substituted to arginine (K68R), or threonine (K68T); and optionally, (4) the insulin-like growth factor 1 (IGF-1) mutant further comprises an amino acid substitution mutation selected from one or more (e.g., two) positions: position 20, position 27, position 29, position 50, position 55, position 64; preferably, the insulin-like growth factor 1 (IGF-1) mutant further comprises an amino acid substitution mutation selected from one or more (e.g., two) positions: D20K, K27R, T29K, R50K, R55K, L64K; wherein each mutated amino acid position is relative to the natural order of amino acid sequence set forth in SEQ ID NO:

1.

7. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, wherein, The insulin-like growth factor 1 (IGF-1) mutant comprises, compared to the amino acid sequence of wild-type human IGF-1, SEQ ID NO: 1: (1) at least an amino acid substitution mutation at position 59; preferably, the methionine at position 59 is substituted to leucine (M59L); (2) at least an amino acid substitution mutation at position 65; preferably, the lysine at position 65 is substituted to arginine (K65R); (3) at least an amino acid substitution mutation at position 68; preferably, the lysine at position 68 is substituted with arginine (K68R); and (4) the mutant further comprises an amino acid substitution mutation selected from two positions: position 20, position 27, position 29, position 50, position 55, position 64; preferably, the mutant further comprises an amino acid substitution mutation selected from two positions: D20K, K27R, T29K, R50K, R55K, L64K; wherein each mutated amino acid position is in the natural order relative to the amino acid sequence set forth in SEQ ID NO:

1.

8. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein, The insulin-like growth factor 1 (IGF-1) mutant comprises, compared to the amino acid sequence of wild-type human IGF-1, SEQ ID NO: 1: (1) at least an amino acid substitution mutation at position 59; preferably, the methionine at position 59 is substituted with alanine (M59A), threonine (M59T), valine (M59V), isoleucine (M59I), leucine (M59L); (2) at least an amino acid substitution mutation at position 65; preferably, the lysine at position 65 is substituted with arginine (K65R), or serine (K65S); (3) at least an amino acid substitution mutation at position 68; preferably, the lysine at position 68 is substituted with arginine (K68R), or threonine (K68T); (4) at least an amino acid substitution mutation at position 27; preferably, the lysine at position 27 is substituted with arginine (K27R); and optionally, (5) the mutant further comprises an amino acid substitution mutation selected from one or more (e.g., 1) positions: position 20, position 29, position 50, position 55, position 64; preferably, the mutant further comprises an amino acid substitution mutation selected from one or more (e.g., 1) positions: D20K, T29K, R50K, R55K, L64K; wherein each mutated amino acid position is in the natural order relative to the amino acid sequence set forth in SEQ ID NO:

1.

9. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to claim 8, wherein, The insulin-like growth factor 1 (IGF-1) mutant comprises, compared to the amino acid sequence of wild-type human IGF-1, SEQ ID NO: 1: (1) at least an amino acid substitution mutation at position 59; preferably, the methionine at position 59 is substituted with leucine (M59L); (2) at least an amino acid substitution mutation at position 65; preferably, the lysine at position 65 is substituted with arginine (K65R); (3) at least an amino acid substitution mutation at position 68; preferably, the lysine at position 68 is substituted with arginine (K68R); (4) at least an amino acid substitution mutation at position 27; preferably, the lysine at position 27 is substituted with arginine (K27R); and (5) the mutant further comprises an amino acid substitution mutation selected from one or more (e.g., 1) positions: position 20, position 29, position 50, position 55, position 64; preferably, the mutant further comprises an amino acid substitution mutation selected from one or more (e.g., 1) positions: D20K, T29K, R50K, R55K, L64K; wherein each mutated amino acid position is in the natural order relative to the amino acid sequence set forth in SEQ ID NO:

1. (5) the mutant further comprises an amino acid substitution mutation at one position selected from the group consisting of: position 20, position 29, position 50, position 55, position 64; Preferably, the mutant further comprises an amino acid substitution mutation at one or more (e.g., 1) positions selected from the group consisting of: D20K, T29K, R50K, R55K, L64K. wherein each mutated amino acid position is in the natural order of the amino acid sequence set forth in SEQ ID NO:

1.

10. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein, The insulin-like growth factor 1 (IGF-1) mutant comprises an amino acid substitution mutation at any one of the following combinations of positions: positions 65, 68; positions 59, 65, 68; positions 59, 65, 68; positions 27, 29, 59, 65, 68; positions 20, 27, 59, 65, 68; positions 27, 50, 59, 65, 68; positions 27, 55, 59, 65, 68; positions 27, 64, 59, 65, 68; positions 27, 59, 68; compared to the amino acid sequence of wild-type human IGF-1, SEQ ID NO:

1. Preferably, the insulin-like growth factor 1 (IGF-1) mutant comprises an amino acid substitution mutation at any one of the following combinations: (i) K65R, K68R; (ii) M59A, K65R, K68R; (iii) M59T, K65R, K68R; (iv) M59V, K65R, K68R; (v) M59I, K65R, K68R; (vi) M59L, K65R, K68R; (vii) K27R, T29K, M59L, K65R, K68R; (viii) D20K, K27R, M59L, K65R, K68R; (ix) K27R, R50K, M59L, K65R, K68R; (x) K27R, R55K, M59L, K65R, K68R; (xi) K27R, L64K, M59L, K65R, K68R; (xii) K27R, M59L, K68R; (xiii) M59L, K65S, K68T; wherein each mutated amino acid position is in the natural order of the amino acid sequence set forth in SEQ ID NO:

1.

11. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, wherein, The insulin-like growth factor 1 (IGF-1) mutant comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 2-14, or an amino acid sequence having at least 90%, e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 2-14.

12. The fatty acidylated derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, wherein, ​ 13. A fatty acid derivative of insulin-like growth factor 1 (IGF-1) or a pharmaceutically acceptable salt thereof, represented by the following general formula: P-(LA) n ;in, P represents an insulin-like growth factor 1 (IGF-1) or a mutant thereof, L represents a linker, A represents a fatty acid, n is an integer from 1 to 5, preferably an integer from 1 to 4; Preferably, P is selected from the peptide chain residue skeleton of a wild-type IGF-1 or a mutant of insulin-like growth factor 1 (IGF-1) as described in any one of claims 2-12; Preferably, L is selected from -(OEG) m1 -(yGlu) m2 - wherein, (OEG) represents -CO-(CH2)-O-(CH2)2-O-(CH2)2-NH-, the -CO- end in (OEG) is connected to P, (γGlu) represents wherein, end 1 is connected to the -NH- end in (OEG) or to P, and end 2 is connected to the -CO- end in A, m1 is an integer from 0 to 5, preferably an integer from 0 to 2, m2 is an integer from 1 to 4, preferably an integer from 1 to 2; Preferably, A is selected from -CO(CH2) p COOH, p is an integer from 14 to 22, preferably an integer from 16 to 18, more preferably 16, 18; Further preferably, -(L-A) is selected from the following structures of formula Z1, Z2, Z3 or Z4:

14. The IGF-1 fatty acid derivative or a pharmaceutically acceptable salt thereof according to claim 13, wherein, The site where the fatty acid A is coupled to P via the linker L is a lysine residue or a glycine residue in the insulin-like growth factor 1 (IGF-1) or the mutant thereof; Preferably, the site where the fatty acid A is coupled to P via the linker L is the epsilon side chain group of a lysine residue or the alpha side chain group of a glycine residue in the insulin-like growth factor 1 (IGF-1) or the mutant thereof; Preferably, the site where the fatty acid A is coupled to P via the linker L is the amino group of the epsilon side chain group of a lysine residue and / or the amino group of the alpha side chain group of a glycine residue in the IGF-1 or the mutant thereof; Preferably, the site where the fatty acid A is coupled to P via the linker L is the amino group of the epsilon side chain group of a lysine residue at all positions and / or the amino group of the alpha side chain group of the first glycine residue in the IGF-1 or the mutant thereof; Preferably, the site where the fatty acid A is coupled to P via the linker L is the amino group of the epsilon side chain group of a lysine residue at all positions, or the amino group of the epsilon side chain group of a lysine residue at all positions and the amino group of the alpha side chain group of the first glycine residue in the IGF-1 or the mutant thereof; Further preferably, the site where the fatty acid A is coupled to P via the linker L is: (i) the amino group of the epsilon side chain of the 27th lysine residue, the amino group of the epsilon side chain of the 65th lysine residue and the amino group of the epsilon side chain of the 68th lysine residue of the wild-type IGF-1; (ii) the amino group of the alpha side chain of the first glycine residue, the amino group of the epsilon side chain of the 27th lysine residue, the amino group of the epsilon side chain of the 65th lysine residue and the amino group of the epsilon side chain of the 68th lysine residue of the wild-type IGF-1; (iii) the amino group of the epsilon side chain of the 27th lysine residue of the IGF-1 mutant; (iv) the amino group of the alpha side chain of the first glycine residue and the amino group of the epsilon side chain of the 27th lysine residue of the IGF-1 mutant; (v) the amino group of the epsilon side chain of the 65th lysine residue of the IGF-1 mutant; (vi) the amino group of the alpha side chain of the first glycine residue and the amino group of the epsilon side chain of the 65th lysine residue of the IGF-1 mutant; (vii) the amino group of the epsilon side chain of the lysine residue at position 29 of the IGF-1 mutant; (viii) the amino group of the alpha side chain of the glycine residue at position 1 and the amino group of the epsilon side chain of the lysine residue at position 29 of the IGF-1 mutant; (ix) the amino group of the epsilon side chain of the lysine residue at position 20 of the IGF-1 mutant; (x) the amino group of the alpha side chain of the glycine residue at position 1 and the amino group of the epsilon side chain of the lysine residue at position 20 of the IGF-1 mutant; (xi) the amino group of the epsilon side chain of the lysine residue at position 50 of the IGF-1 mutant; (xii) the amino group of the alpha side chain of the glycine residue at position 1 and the amino group of the epsilon side chain of the lysine residue at position 50 of the IGF-1 mutant; (xiii) the amino group of the epsilon side chain of the lysine residue at position 55 of the IGF-1 mutant; (xiv) the amino group of the alpha side chain of the glycine residue at position 1 and the amino group of the epsilon side chain of the lysine residue at position 55 of the IGF-1 mutant; (xv) the amino group of the epsilon side chain of the lysine residue at position 64 of the IGF-1 mutant; or (xvi) the amino group of the alpha side chain of the glycine residue at position 1 and the amino group of the epsilon side chain of the lysine residue at position 64 of the IGF-1 mutant.

15. The IGF-1 fatty acidylated derivative or a pharmaceutically acceptable salt thereof of claim 13 or 14, comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 15-31, or an amino acid sequence having at least 90%, e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 15-31; Preferably, the IGF-1 fatty acidylated derivative is selected from the group consisting of C-P1370011, C-P1370009, C-P1370001, C-P1370002, C-P1370003, C-P1370004, C-P1370010, C-24B0320003, C-24B0320004, C-24B0320007, C-24B0320013, C-24B0320015, C-24B0320016, C-24B0320017, C-24B0320018, C-24B0320019, C-24B0320038 as set forth in Table 2. Preferably, the IGF-1 fatty acidylated derivative is selected from the group consisting of C-P1370011, C-P1370009, C-P1370001, C-P1370002, C-P1370003, C-P1370004, C-P1370010, C-24B0320003, C-24B0320004, C-24B0320007 as set forth in Table 2.

16. A method of preparing the IGF-1 fatty acidized derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1-15, comprising reacting said IGF-1 or a mutant thereof with said fatty acid under conditions such that said fatty acid is chemically bound to an amino group of said IGF-1 or a mutant thereof.

17. A pharmaceutical composition of the IGF-1 fatty acidized derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1-15, and a pharmaceutically acceptable carrier and / or excipient.

18. Use of the IGF-1 fatty acidized derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1-15, or the pharmaceutical composition of claim 17, in the manufacture of a medicament for treating primary IGF-1 deficiency or a disease ameliorated by IGF-1. Preferably, the disease or condition includes, but is not limited to, growth retardation caused by primary IGF-1 deficiency, such as short stature, skeletal dysplasia, muscle system dysplasia, facial and body features abnormalities, and other system dysplasia, Growth Hormone Insensitivity Syndrome (GHIS), growth impairment caused by growth hormone receptor deficiency (i.e. Laron Syndrome); a disease ameliorated by IGF-1, such as bronchopulmonary dysplasia (BPD) in premature infants, Retinopathy of Prematurity (ROP), brain injury in premature infants (including Germinal Matrix Hemorrhage and Intraventricular Hemorrhage (GM-IVH), Periventricular Hemorrhagic Infarction (PVHI) and White Matter Injury (WMI)), Acute Myocardial Infarction (AMI), stroke, Acute Ischemic Stroke (AIS), cerebral apoplexy, Acute Ischemic Cerebral Apoplexy, improvement of neurological deficit in patients with Acute Ischemic Stroke or Cerebral Apoplexy, diabetes, neurodegenerative diseases, cartilage repair, deafness, autism.

19. A method of treating primary IGF-1 deficiency or a disease ameliorated by IGF-1, comprising administering to a subject in need thereof an effective amount of the IGF-1 fatty acidized derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1-15, or the pharmaceutical composition of claim 17. Preferably, the disease or condition includes, but is not limited to, growth retardation caused by primary IGF-1 deficiency, such as short stature, growth retardation, skeletal dysplasia, muscle system development deficiency, facial and body feature abnormality, and other system development disorder, Growth Hormone Insensitivity Syndrome (GHIS), growth disorder caused by growth hormone receptor deficiency (i.e. Laron Syndrome); IGF-1 improvable diseases, such as bronchopulmonary dysplasia (BPD) in premature infants, retinopathy of prematurity (ROP) in premature infants, brain injury in premature infants (including Germinal Matrix Hemorrhage and Intraventricular Hemorrhage (GM-IVH), Periventricular Hemorrhagic Infarction (PVHI), and White Matter Injury (WMI)), acute myocardial infarction (AMI), stroke, acute ischemic stroke (AIS), cerebral apoplexy, acute ischemic cerebral apoplexy, acute ischemic stroke or cerebral apoplexy, neurological deficit improvement in patients with acute ischemic stroke or cerebral apoplexy, diabetes, neurodegenerative disease, cartilage repair, deafness, autism.

20. Use of the IGF-1 fatty acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, or the pharmaceutical composition according to claim 17, in the manufacture of a medicament for treating a disease caused by external causes or internal causes of vascular obstruction, vascular rupture, brain nerve cell damage, and neurodegeneration. Preferably, the disease caused by the blood vessel obstruction, blood vessel rupture, brain nerve cell damage includes: Acute myocardial infarction, acute ischemic stroke (AIS), cerebral apoplexy, acute ischemic cerebral apoplexy, hemorrhagic stroke, traumatic brain injury (TBI), autism, amyotrophic lateral sclerosis.

21. Use of the IGF-1 fatty acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, or the pharmaceutical composition according to claim 17, in the manufacture of a medicament for treating a premature infant development-related disease or perinatal injury disease. Preferably, the premature infant development-related disease or perinatal injury disease includes bronchopulmonary dysplasia (BPD) and diseases related thereto.

22. Use of the IGF-1 fatty acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, or the pharmaceutical composition according to claim 17, in the manufacture of a medicament for treating a disease caused by external causes or internal causes of vascular obstruction, vascular rupture, brain nerve cell damage, and neurodegeneration. Acute myocardial infarction, acute ischemic stroke (AIS), cerebral apoplexy, acute ischemic cerebral apoplexy, hemorrhagic stroke, traumatic brain injury (TBI), autism, amyotrophic lateral sclerosis.

23. Use of the IGF-1 fatty acid derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, or the pharmaceutical composition according to claim 17, in the manufacture of a medicament for treating a premature infant development-related disease or perinatal injury disease. Preferably, the premature infant development-related disease or perinatal injury disease includes bronchopulmonary dysplasia (BPD) and diseases related thereto. Preferably, the BPD-related disease comprises: Retardation in growth and development after birth in preterm infants, retardation in mental development after birth in preterm infants, death after birth in preterm infants, bronchopulmonary dysplasia associated pulmonary hypertension (BPD-PH), retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH) in preterm infants, including white matter injury (WMI) or periventricular leukomalacia (PVL) in preterm infants, necrotizing enterocolitis (NEC), cardiopulmonary insufficiency due to BPD and growth retardation.